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Ovarian cancer (OC) is the fourth most common cancer in women, and the most 
lethal gynecologic malignancy in the United States.  Adequate screening methodologies are 
currently lacking and most women first present with either stage III or IV disease. To date, 
there has been no substantial decrease in death rates and the majorities of patients relapse 
and die from their disease despite response to first-line therapy.  Several proteins, such as 
CA-125, are elevated in OC, but none has proven specific and sensitive enough to serve as a 
screening tool or for tumor cell recognition and lysis.   It has been proposed that human 
endogenous retrovirus sequences (HERVs) may play a role in the etiology of certain 
cancers. In a previous study, we showed that HERV-K envelope (env) proteins are widely 
expressed in human invasive breast cancer (BC) and ductal carcinoma in situ (DCIS), and 
elicit both serologic and cell-mediated immune responses in BC patients.  We also reported 
the expression of multiple HERV genes and proteins in OC cell lines and tissues. In this 
study, we strengthened our previous data by determining that HERV-K env mRNAs are 
expressed in 69% of primary OC tissues (n=29), but in only 24% of benign tissues (N=17).  
Immmunohistochemistry (IHC) staining revealed HERV-K positive cancer cells detected in 
endometrioid adenocarcinoma and serous adenocarcinoma but not in benign cyst or normal 
epithelium biopsies.  Immunofluorescence staining (IFS) showed greater cell surface 
expression of HERV-K in OC samples compared to adjacent uninvolved samples.  Enzyme-
vi 
linked immunosorbent assay (ELISA) data confirmed that a humoral immune response is 
elicited against HERV-K in OC patients.  T-cell responses against HERV-K in lymphocytes 
from OC patients stimulated with autologous HERV-K pulsed dendritic cells included 
induction of T-cell proliferation and IFN-γ production.  HERV-K–specific cytolytic T cells 
induced greater specific lysis of OC target cells compared to benign and adjacent uninvolved 
target cells.   Finally, upon T regulatory cell (T-reg) depletion, 64% of OC patients 
displayed an increase in the specific lysis of target cells expressing HERV-K env protein. 
These findings suggest that HERV-K env protein is a tumor-associated antigen capable of 
activating both T-cell and B-cell responses in OC patients, and has great potential in the 
development of  immunotherapy regimens against OC. 
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 Chapter 1:  Introduction 
1.1  Retroviruses 
Retroviruses are RNA viruses that are duplicated in a host cell via reverse 
transcriptase (RT) to produce viral genomic DNA, which is then incorporated into the host’s 
genome.  Subsequent retroviral replication occurs concomitantly with the host cell’s DNA.  
This reverse flow of genetic information from RNA to DNA and the establishment of DNA 
in an integrated form in the host genome are defining aspects of retroviruses.  The virion 
particles, approximately 100nm in diameter,  are spherical and are surrounded by an 
envelope consisting of a lipid membrane bilayer.  The surface is studded by projections of 
an envelope glycoprotein.  Beneath the membrane is a spherical layer of protein, called the 
capsid protein, and an internal nucleocapsid.  Based on new genera named by the 
International Committee on Taxonomy of Viruses, simple retroviruses encode only the Gag, 
Pro, and Env gene products.  In addition to these gene products, complex retroviruses 
encode an array of small regulatory proteins with a range of functions.  The cleavage of 
Gag, Pol and Env precursors forms the products in the mature infectious virions including 
the following proteins:   membrane-associated matrix protein, capsid, nucleocapsid, 
protease, dUTPase, reverse transcriptase, integrase, surface protein (SU), and 
transmembrane (TM) protein 1.  Virus particles contain 2 copies of RNA of ~8 to 10 kb in 
length (Figure 1). 
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Figure 1:  Schematic structure of a retroviral particle.   The surface is studded by projections 
of an envelope glycoprotein consisting of the SU and TM proteins.  The matrix protein and 
core shell derived from gag are depicted in the center of the virus.  The 2 RNA molecules, 
polymerase, RNAse, and integrase are shown within the core shell.    
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Typically, the targets of retroviruses are somatic cells, however, when the target is a 
gamete, the provirus becomes a permanent fixture within the offspring’s genome.  Literally 
meaning “born within”, these endogenous retroviruses (ERVs) are then inherited across 
generations.  Some of these elements first entered the primate genome more than 40 million 
years ago.  However, new proviral copies have been generated more recently that are human 
specific 2, 3.  Human endogenous retroviruses (HERVs) are believed to have entered the 
human genome around 30 million years ago via infection of the germline, and since then 
have persisted as stably integrated, vertically transmitted proviruses 4, 5.  When we examine 
the collective genome of Homo sapiens we find that humans share most of their ERVs with 
chimpanzees, great apes, gibbons, and old world monkeys 6, 7.  HERVs comprise up to 8% 
of the human genome and are widely dispersed 8.  HERVs lack mutagenic activity and in 
fact nearly 90% of HERV elements exist as recombined solitary long terminal repeats 
(LTRs) 8, 9 and the remainder have accumulated inactivating mutations during evolution 10.  
Specifically, the majority of HERVs are incomplete and faulty in terms of replication due to 
multiple termination sequences 11-15.  In most cases HERVs are transcriptionally silenced by 
epigenetic mechanisms including methylation, histone modifications, and small RNAs.  
However, our knowledge of how these modifications demarcate and silence HERVs in the 
human genome is limited. 
HERVs belong to the class of retroelements, which can be subdivided into elements 
with regulatory LTRs  (8.3% of our DNA; 0.3 x 106 copies) and elements without LTRs 
(33.9%; 2.4 x 106 copies) 16.  Short and long interspersed nuclear elements (SINEs and 
LINEs), members of the non-LTR group, are present in very high copy numbers.  LINEs are 
abundant retrotransposons that comprise approximately 20% of mammalian genomes.  
4 
LINEs encode a RT that can be utilized for retrotranspositions of SINEs and LINEs or for 
the formation of pseudogenes 16.  The LTR containing retroelements can further be divided 
into 6 superfamilies 17, based solely on sequence relationship:  class I (gamma retroviruses) 
representing most families and the largest genomic fraction 9, 18, class II (beta retroviruses) 
which contain the HERV-K elements and older families 19, and class III (spuma 
retroviruses) 9 which contain the oldest recognizable HERV elements 8.  The other 
superfamilies MER4, MST and MLT represent ancient retrotransposons with no known 
functions in humans 16.   
1.2  HERV-K(HML2) (human MMTV-like 2) Family 
HERVs are classified into families according to the single-letter amino acid code 
corresponding to the tRNA primer used for reverse transcription of the HERV genome 20.  
Thus, HERV-K’s tRNA primer begins with lysine, HERV-W’s begins with tryptophan and 
so on.   The type K family (HERV-K) proviruses are present at approximately 30-50 copies 
per haploid human genome, but many are polymorphic in humans.   HERV-K is located on 
chromosome 19 and possesses large open reading frames in the genes putatively encoding 
Gag, Pol, Env and a protease, flanked by two non-coding LTRs 21 (Figure 2).  Therefore, 
HERV-Ks contain all structural features necessary for viral replication 21.  The gag gene 
encodes matrix, capsid (core shell proteins) and nucleocapsid proteins necessary for viral 
RNA encapsidation and particle formation.  The pol gene encodes the viral enzyme 
machinery needed for conversion of the viral RNA to the proviral DNA form, including  RT 
and integrase.   The env gene encodes for two different proteins important for virus 
infectivity:  an outer surface membrane (SU) protein and a transmembrane (TM) protein.  
5 
The LTRs contain elements involved in transcription initiation and termination 22.  HERV-K 
possesses 2 accessory proteins termed Rec and Np9.  Rec, a protein functionally related to 
HTLV Rex and HIV Rev, is responsible for the nuclear export of unspliced or single-spliced 
viral mRNA into the cytoplasm.  Np9 is a nuclear protein.   
Several studies have led to the identification of 18 coding env genes, with the most 
important contributor being the HERV-K(HML2) family23-25 which contains six coding env 
genes.  The entry dates of all six copies with a coding env are less than five million years 
ago.26, 27 
In 1986, Ono M, Yasunaga T, Miyata T, and Ushikubo H,  determined the complete 
nucleotide sequence of the human endogenous retrovirus genome HERV-K10, a member of 
the human endogenous retrovirus HERV-K family.  The sequence was shown to be a full-
length 9.2-kb provirus with LTRs at each end 21.  HERV-K22, another member, contained 
an additional 292-bp sequence between the pol and env genes.  Subsequently, the genome 
missing the 292-bp sequence was designated “type 1” and the genome containing the 292-bp 
sequence “type 2” 28.  The 292 bp deletion found in HERV-K type I leads to the fusion of 
the pol and the env gene and the absence of the rec gene. HERV-K type II, the HERV-K 
prototype, has open reading frames (ORFs) for the structural proteins Gag and Env, RT 29, 
and the regulatory protein Rec 30. These two types contain ORFs encoding genes required 
for retroviral replication (Figure 2).   
 
 
6 
 
Figure 2:  Schematic representation of full-length HERV-K(HML-2) type 1 and 2 
proviruses and their respective mRNA transcripts. There are three genetic domains, flanked 
by the regulatory LTRs.  The gag domain encodes for matrix and core shell (capsid) 
proteins, the pol encodes for reverse transcriptase, protease, integrase and ribonuclease, and 
the env encodes for the surface and transmembrane proteins.  Splice donor (SD) and splice 
acceptor (SA) sites are shown.  There are two types of HERV-K (HML-2) proviruses in the 
human genome differing by the presence (type 2; black rectangle) or absence (type 1;D292-
bp) of a 292-bp sequence at the pol-env boundary 28.  HERV-K(HML-2.HOM) is an 
example of a type 2 provirus, HERV-K101 an example of a type 1 provirus.  In type 2 
proviruses, the 292-bp sequence harbors a splice donor site (SD2b) involved in the 
generation of doubly spliced transcripts coding for the two exons (light grey and dark grey 
boxes) of the accessory ~15kDa protein Rec by some type 2 proviruses 30, 31.  In type 1 
proviruses, an alternative splice donor (SD2a) located upstream of the 292-bp stretch is used 
to generate mRNAs coding for Np9 32.  Np9 is an ~9 kDa, 74-amino acid protein that shares 
its 14 N-terminal amino acids (exon 1, light grey box) with Rec and Env, whereas the 60 C-
terminal amino acids (exon 2, dark grey box) are derived from the third (non-Rec, non-Env) 
ORF.  Numbers on top of rec and np9 transcripts indicate the reading frames.  Adopted from 
reference 33 with permission from Springer. 
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1.3  Normal physiological effects of HERV 
A very small proportion of HERVs can potentially encode proteins, however this 
proportion has led to a multitudinous amount of data showing that these and other defective 
copies are actively transcribed.  This insinuates that many LTRs possess retained 
transcriptional regulatory functions that confer a beneficial function.  Indeed, the fact that 
HERVs constitute approximately 8.3% of the human genome efficaciously asserts the theory 
that HERVs have provided some evolutionary advantages at the population level, and in fact 
several advantages have been proposed.  First, HERVs constitute sequences that are 
substrates for genomic rearrangements and therefore could contribute to modeling and the 
plasticity of the genome 33.  Also of importance, retroviral LTRs naturally possess enhancer, 
promoter, and polyadenylation activities 34.  Therefore HERV LTRs can provide tissue-
specific enhancers, alternative promoters, or alternative polyadenylation signals for nearby 
genes 18.   Indeed, LTRs function as promoters of retroviral genes and sometimes function as 
promoters of nearby cellular genes 35-38.  In fact, at least 50% of the human-specific HERV-
K LTRs act in vivo as active promoters for non-repetitive DNA transcription 39.  For 
example, HERV LTRs account for over 30% of all p53 binding sites genome-wide, 
therefore contributing to the anti-oncogenic function of p53 40.  Also, Mager DL, Hunter 
DG, Schertzer M, and Freeman JD, identified two human genes, HHLA2 and HHLA3, for 
which HERV-H LTR served as the primary polyadenylation signal.  Although the functions 
of the particular genes were unknown, this data supports the fact that retroviral LTRs 
assume gene regulatory functions 41. 
8 
Another advantage is the possibility that the presence of ERVs may protect 
organisms from infections by related exogenous retroviruses via receptor interference 42, 43.  
For example, HERV-W envelope glycoproteins have been shown to confer cellular 
resistance to superinfection by exogenous retroviruses 44.  Finally, to support the idea of 
physiological in vivo functions of HERV-encoded proteins, Mi S, Lee X, Li X, Veldman 
GM, Finnerty H, Racie L, LaVallie E, Tang XY, Edouard P, Howes S, Keith JC Jr, and 
McCoy JM, showed in 2000, that the env protein of HERV-W, termed Syncytin-1, mediates 
the formation of syncytiotrophoblasts from cytotrophoblasts which is a key step in normal 
placental morphogenesis 45-47.  Another example of beneficial functions of HERV-encoded 
proteins involves HERV-E, which is activated in a proportion of renal cancer cells.  In a 
recent clinical study, HERV-E provided target antigens recognizable by cytotoxic T cells 
from donors after allogenic hematopoetic stem cell transplantation, leading to complete or 
partial tumor regression in patients 48. 
1.4   HERV and Human Disease 
One hundred years after Francis Peyton Rous demonstrated that cancer could be 
caused by a virus, science has elucidated seven human viruses that have been found to cause 
10-15% of human cancers worldwide.  The International Agency for Research on Cancer 
estimates that one in five cancer cases worldwide are caused by infection, with most caused 
by viruses 49, 50.  These cancers are serious public health problems but most importantly 
these cancers have readily identifiable targets for diagnosis, prevention and therapy 51.  
Vaccination programs against hepatitis B virus (HBV) and human papilloma-virus (HPV), 
both human tumor viruses, have already made huge impacts on worldwide cancer rates 52-54.   
9 
However, modern science has since shown that in human cancer, virus infection alone is not 
sufficient for tumorigenesis.  Cancer is a complex multistep process and it is the culmination 
of various molecular events that generate the final transformed cellular phenotype.  Viruses 
can be divided into two groups based on the roles they play in tumorigenesis.  Direct 
carcinogens express viral oncogenes in each cancer cell that directly contribute to cancer cell 
transformation and indirect carcinogens cause cancer through chronic infections and 
inflammation, ultimately leading to carcinogenic mutations 55.  With respect to HERV-K, 
the exact role it plays in cancer is unknown and future studies are needed to determine its 
carcinogenic effects.   
For many decades, HERV expression at the protein and RNA levels was found to be 
associated with cancer and autoimmune diseases 56-59.  Indeed, the expression, promoter 
activity, and epigenetic regulation of HERV-Ks are extremely different between malignant 
and normal cells.  Numerous studies have documented an increased expression of HERVs in 
terms of both transcriptional and protein levels in tumors, with the majority of research on 
the HERV-K family (Table 1).   
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Table 1:  Expression of HERVs in human cancer:  Expression of various HERV types is 
shown in various tumor types.  The detection of viral genes at the transcriptional (RNA) or 
translational levels (P) is shown.  Adapted from reference 10 with permission from Elsevier. 
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At the time the complete nucleotide sequence of HERV-K10 and HERV-K22was 
determined 21, the types, structures, and functions of human endogenous retroviruses and 
their relationships to human cancer were not known.  However, Ono and his colleagues 
advocated the possibility that a particular antigen expressed in human BC tissue and T47D 
cells was the env gene product of a potentially active HERV-K provirus.  The following 
year, Ono M, Kawakami M, and Ushikubo H  determined that stimulation of HERV-K 
genome expression was observed in the human BC cell line T47D after estradiol treatment 
60
.  Correspondingly, Lower R, Lower J, Tondera-Koch C, and Kurth R demonstrated that 
upon steroid hormone treatment, human teratocarcinoma cells showed an increase in 
expression of the HERV-K genome and production of retroviral-like particles 61.  Similarly 
to the teratocarcinoma cells and supporting the data from the previous studies, T47D cells 
also showed an increase in the expression of the HERV-K genome and the production of 
retroviral-like particles upon hormone stimulation 62-64.  In addition, Etkind PR, Lumb K, Du 
J, and Racevskis J determined that T47D contains the type 1 HERV-K genome which is 
spliced to subgenomic transcripts 65.  
Willer and his colleagues were the first to characterize the HERV-K env 
transcription pattern in several malignant tissues and in peripheral blood mononuclear cells 
(PBMCs) via RT-PCR 66.  HERV-K env transcripts were found in all of the following 
tissues: BC, Hodgkin’s disease, thyroid adenoma (TA), colon cancer, chronic myelogenous 
leukemia (CML), high and low grade non-Hodgkin’s lymphomas, and myelodysplastic 
syndrome.  HERV-K env transcripts were also found in PBMCs from patients with gastric 
cancer, and BC.   
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In 2001, Wang-Johanning F, Frost AR, Johanning GL, Khazaeli MB, LoBuglio AF, 
Shaw DR, and Strong TV investigated the expression of HERV sequences in BC and 
determined that indeed HERV-K transcripts are specifically and frequently expressed.  The 
group further substantiated their results by determining that some of these transcripts 
contained ORFs that produced env protein 67.  To build on this knowledge, the same group 
investigated the expression of type 2 HERV-K env mRNAs and the splicing patterns of both 
types of HERV-K in human BC tissues.   They discovered that there was an increase in 
HERV-K env and spliced env expression in human BC tissues.  Specifically, type 2 HERV-
K env transcripts were detected in human BCs.  Of great importance, expression was 
significantly higher in most BC tissues than in normal breast tissues 68.     
In an exceptional study by Dewannieux M, Blaise S, and Heidmann T, it was 
demonstrated that a member of the HERV-K family, termed K108, encoded a functional env 
protein 69.  They discovered that the env protein was exported to the cell surface, cleaved 
into SU and TM subunits, and generated infectious pseudotyped particles.  Combined with 
the data that HERV-K-related particles had been detected in culture supernatants from 
teratocarcinoma and melanoma cell lines, these findings gave credence to the idea that 
infectious retroviruses could be produced if they incorporated the HERV-K108 env protein 
3, 24, 28, 70
. 
Another study by Dewannieux and his colleagues helped to unify the preceding 
results by showing it was possible to derive the sequence of HERV-K and construct a 
consensus HERV-K provirus, which they termed Phoenix 71.  The element produced viral 
particles complete with structural and functional properties of a retrovirus and had the ability 
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to infect human cells.  Upon infection, Phoenix integrated with the exact signature of the 
presently found endogenous HERV-K progeny.  Significantly, they showed that in vitro 
recombination among present-day human HERV-K loci can generate functional elements, 
indicating the possibility that human cells can produce infectious retroviruses 71.   Similarly, 
in an exciting 2008 paper, Boller and his colleagues proved that the HERV-K provirus is 
capable of producing intact retroviral particles when cloned into a baculovirus expression 
vector, exposing a real-life active human endogenous retrovirus of today 72.   
Studies reporting the presence of retrovirus-like particles in human melanomas date 
back to the 1970s 73, 74, however it wasn’t until 2003, that Muster T, Waltenberger A, and 
Grassauer A made a novel discovery by showing that retrovirus-like particles, which exhibit 
RT activity and have homologous sequences to HERV-K, are produced by human 
melanoma cells.  This group also showed expression of the pol gene and Gag, Env, and Rec 
proteins in human melanomas.  Most importantly, these expressions were not seen in 
melanocytes or normal lymph nodes 75.  To supplement this data, Buscher K, Trefzer U, 
Hofmann M, Sterry W, Kurth R, and Denner J, showed expression of viral proteins in 
melanomas and the presence of HERV-K-specific antibodies in patients with melanomas 76.  
Hahn S, Ugurel S, Hanschmann HM, Strobel H, Tondera C, Schadendorf D, Lower J, and 
Lower R expounded on the discovery that expression of HERV-K proteins induce humoral 
immune responses in melanoma, and showed that serological response to HERV-K 
correlated with survival probability in melanoma patients.  The hope at that point was the 
possibility of using anti-HERV-K reactivity as a way to monitor patients suffering from 
melanoma 77.   
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A key paper in the discovery of potential mechanisms of HERV-K came from 
Serafino A, Balestrieri E, Piermarchi P, Matteucci C, Moroni G, Oricchio E, Rasi G, 
Mastino A, Spadafora C, Garaci E, and Vellabona PS  78.  He and his colleagues 
demonstrated that human melanoma cell lines undergo a variety of morphological and 
molecular alterations typical of malignant cells in response to a massive HERV-K 
expression and subsequent production of HERV-K-related viral-like particles.  This strongly 
indicated that activation of HERV-K expression is a key element in morphological and 
functional cell changes during melanoma progression 78. 
Several groups have found cytotoxic T-lymphocyte (CTL) responses against HERV-
K antigens in melanoma patients and seminoma patients 79, 80.  The first evidence that 
HERV-encoded peptides expressed in human tumor cells could also be targets for antitumor 
cytotoxic CD8+ T cell responses, came from a study that identified a HERV-K (HML-6)-
encoded HLA-A2-restricted peptide (HERV-K-Mel) which was recognized in autologous 
melanoma cells by CTLs from two patients with melanomas 80.   This suggested that HERV-
K proteins can function as tumor antigens that are targeted by CTLs and could potentially be 
used for vaccination. 
In terms of research on expression of HERV families in other cancers, a paper by 
Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV, 
Nickerson ML, Merino M, Hong JA, Schrump DS, Srinivasan R, Linehan WM, Tian X, 
Lerman MI, and Childs RW showed that HERV-E is expressed in renal cell carcinoma 
(RCC) and is highly immunogenic 81.  HERV-E expression has also been implicated in 
prostate cancer 82 and a recent study by Ishida T, Obata Y, Ohara N, Matsushita H, Sato S, 
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Uenaka A, Saika T, Miyamura T, Chayama K, Nakamura Y, Wada H, Yamashita T, 
Morishima T, Old LJ, and Nakayama E identified the HERV-K gag protein in serum from 
prostate cancer patients 83.  HERV-H expression has been shown in gastrointestinal cancer 
84
.  Transcripts containing the HERV-A LTR sequence were even found in a lung cancer cell 
line with no transcripts detectable in normal lung tissue 85.  HERV-K-MEL was found to be 
expressed with a high prevalence in pancreatic cancer patients 86.   In terms of diseases other 
than cancer, it has been shown that HERV-K viral load can be detected in plasma samples 
from rheumatoid arthritis patients.  Specifically, viral load is higher in plasma samples from 
those with active disease 87.  HERVs have also been shown to be expressed in brain from 
patients with multiple sclerosis 88, 89.  In an innovative study, Contreras-Galindo R, Kaplan 
MH, Markovitz DM, Lorenzo E, and Yamamura Y  illustrated that type 1 and type 2 HERV-
K viral RNA genomes were found to coexist in the same plasma of HIV-1 patients 90.  The 
same group later showed that HIV-1 viral particles upregulated HERV-K RNA in a dose-
dependent manner 91.   Extending these results, it was also observed that HERV (-H, -K, and 
-L family)-specific T cell responses in HIV-1-infected individuals were identified and 
inversely correlated with HIV-1 plasma viral load and positively correlated with CD4+ T 
cells counts.  These results generated the idea that HERV-specific T cells may potentially 
participate in controlling HIV-1 replication and that therapeutics targeting HIV-1-infected 
cells with HERV specific cytotoxic T cells could be beneficial 92, 93.   
1.5  HERV-K in BC in our laboratory 
For many years our laboratory has focused on BC and HERV-K env protein 
expression.  In 2008, we demonstrated that HERV-K env proteins are strongly expressed in 
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human invasive BC and DCIS, and are correlated with lymph node metastasis in comparison 
with adjacent benign tissues. We further showed that HERV-K env protein elicits both 
serologic and cell-mediated immune responses.  Specifically, CD8+ T-cell proliferation 
specific for HERV-K was detected in PBMCs in a high proportion of BC patients after in 
vitro stimulation with the HERV-K protein.  CD8+ cytotoxic T-cells also specifically killed 
HERV-K expressing established target cells.  More importantly, little or no responses were 
detected in lymphocytes from normal donors 94. 
To reinforce these conclusions, we obtained samples from new patient cohorts from 
the U.S. and China and illustrated that the HERV-K env gene is expressed in the majority of 
BC samples from both cohorts but not in adjacent noncancerous tissue or normal breast 
tissue.  HERV-K env protein expression was significantly associated with disease stage, a 
positive node status, and poor disease outcome, suggesting expression may enhance 
metastatic spread in women diagnosed with BC.  However, HERV-K env expression was 
not associated with age, ER or PR protein expression, or histological grade.   We therefore 
concluded that activation of HERVs appear to be a common event in BC regardless of 
geographic location.95 
In 2012, we combined our HERV-K knowledge with cancer immunotherapeutics and 
were the first to show that monoclonal and single-chain antibodies against the HERV-K env 
were capable of blocking growth and proliferation, and inducing apoptosis of human BC 
cells in vitro.  We also demonstrated that treatment with an anti-HERV-K monoclonal 
antibody (mAb) significantly inhibited tumor growth in mice bearing BC xenograft tumors 
96
. 
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1.6  Proposed functions of HERVs in Human Disease 
HERVs have been implicated in the pathogenesis of diseases, in particular cancer 
and autoimmunity 97, however the specific role they play remains an enigma.  HERVs have 
resided in their host genomes for millions of years and still show similarities with exogenous 
infectious retroviruses with respect to internal genome organization and the presence of 
LTRs.  The idea that endogenous retroviral elements play key biological roles is bolstered 
by their significant distribution in mammalian genomes.  Therefore, much consideration had 
been given to the specific functions of HERVs in these biological roles, producing several 
diverse mechanisms (Figure 3).  Firstly, HERVs could be acting as intra or inter-
chromosomal recombination sites causing genomic plasticity and chromosomal aberrations.  
Non-allelic homologous recombination (NAHR) between members of the same endogenous 
viral element family that are located on the same or different chromosomes may lead to 
genomic rearrangements such as deletion, duplication, inversion or translocation events 98.  
A recent study of HERV-K shows that 6 (17%) of the 35 full-length copies examined have 
undergone some form of NAHR following insertion 99.    Indeed somatic rearrangements 
might be relevant for tumorigenesis, for example, a recurrent translocation event that creates 
an oncogenic HERV-K-ETS translocation variant 1 (ETV1) fusion gene has been implicated 
in prostate cancer 100.  Secondly, proviral insertions may produce somatic or germ line 
mutations resulting in a loss of cellular gene function.  Even though no replication-
competent HERV has been identified in the human genome to date, the idea of insertional 
mutagenesis continues to be of considerable interest.  Thirdly, solitary or proviral LTRs 
could possibly modulate adjacent cellular gene expression.  Finally, expression of HERV 
specific proteins may have a pathological influence 22 (Figure 3). 
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Two processes implicate the mechanism of tumor immune escape mediated by 
immunosuppressive endogenous retroviral Env proteins.  One process is in the induction of 
immune tolerance at the materno-fetal barrier via a physiological expression in the placenta 
101
.  The other process is the suppression of an antitumoral immune response through 
aberrant expression in cancers.  Also, data has shown that HERV-K accessory proteins, both 
Rec and Np9, have demonstrated oncogenic properties.  The first strong evidence that Rec 
expression causes the development of germ cell tumors in vivo, was by Boese A, Sauter M, 
Galli U, Best B, Herbst H, Mayer J, Kremmer E, Roemer K, Mueller-Lantzsch N in 2000 
102
.  To understand the molecular mechanisms underlying the oncogenic effect seen in Rec 
expression, studies were executed to discover proteins that interacted with Rec. One of these 
proteins was the promyelocytic leukemia zinc finger (PLZF) protein 102, which is a tumor 
suppressor, transcriptional repressor of the c-myc proto-oncogene, and spermatogonial stem 
cell regulator.  Cells stably transfected with PLZF and Rec showed increased cell 
proliferation and a reduced apoptosis rate compared to cells stably transfected with PLZF 
alone 103.   After Np9 was identified 103,  np9 transcripts were detected among malignant 
cells but not in normal cells 32.  Np9 was later found to directly interfere with an ubiquitin 
ligase that regulates the transcription factor Notch via degradation of the Notch-antagonist 
Numb104.  The Numb/Notch pathway is an essential part of the proproliferative Ras 
signaling, and more importantly has been suggested to be involved in germ cell tumors by 
causing genetic instability 105.  The regulation and effector pathways of Rec and Np9 need to 
be further explored in order to determine the complete contribution of these proteins in 
human disease. 
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Figure 3:  Possible mechanisms by which HERVs could be involved in tumorigenesis. A 
simplified scheme of tumorigenesis and potential fates of malignant cells is depicted to 
indicate steps in tumorigenesis in which HERVs may play a role. The process by which a 
normal cell (green nucleus) turns into a cancer cell (red nucleus) is referred to as malignant 
transformation. Possible mechanisms by which HERVs contribute to malignant 
transformation are listed. Malignant cells are normally controlled by the immune system 
(tumor immunosurveillance). Expression of HERV antigens (HERV-Ags, green squares) on 
tumor cells may elicit an antitumor immune response involving, among others, antibodies 
(Ab) and CD8+ cytotoxic T cells (CTL). Ideally, antitumor immune responses result in the 
elimination of cancer cells. Expression of immunosuppressive endogenous retroviral 
envelope (Env, yellow triangle) proteins on tumor cells may lead to a CD4+CD25+ 
regulatory T cell (T-reg)-mediated suppression of antitumor CTL, leading to escape of 
tumor cells from immunosurveillance (tumor escape) and consecutive invasive cancer 
growth.  The level of evidence of the outlined mechanisms for human cancers is indicated. * 
Some evidence for potential relevance in human cancer (germ cell tumors). ** Evidence in 
animal models, so far no evidence in humans. *** Hypothetical mechanism. **** Some 
evidence for anti-HERV immune responses in certain human cancers; very limited data 
concerning their functional relevance.  Adapted from reference 33 with permission from 
Springer.   
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1.7  Ovarian Cancer 
Ovarian cancer (OC) is the most common cause of death in gynecologic 
malignancies and its prognosis has only modestly improved over the last few decades 106. 
Epithelial OC, the main type of this disease, accounts for more than 90% of all malignant 
ovarian tumors.  Despite improvements in systemic therapy, advanced OC remains highly 
lethal with more than 90% of patients developing tumor recurrence, resulting in five-year 
survival rates of only 30% 107.  The incidence and mortality rate of OC has remained 
unchanged over the past decade and there is an obvious need for more sensitive markers to 
detect OC at an early stage and to monitor disease progress.  Currently there is no test with 
sufficient predictive value for use in screening and detection of pre-malignant or localized 
OC 108, and 70% of patients with OC present with advanced disseminated disease at the time 
of initial diagnosis 109.  Therefore, the identification of novel diagnostic serum biomarkers 
specific to and widely expressed by early-stage OCs is urgently needed for the future 
development of diagnostic tests for early detection and for development of new 
immunotherapy regimens 108.    
There are six tumor subclasses distinguishing patients with epithelial OC 110.  The 
most common form is termed serous carcinomas and represents 40% of all cases.  The 
remaining epithelial ovarian cancer subclasses are endometrioid, mucinous, clear cell, 
transitional, and undifferentiated.  Approximately 90% of epithelial ovarian cancers are 
sporadic, and the remaining 10% are associated with inherited mutations in the BRACA1 or 
BRACA2 functions 111, 112.  Due to their anatomical location, a high percentage of ovarian 
tumors disseminate throughout the peritoneal cavity and implant on various organs, thereby 
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forming ascites.  The following stages represent degrees of tumor dissemination:  stage I-II 
disease is confined to one or both ovaries, stage III disease shows peritoneal spread, and 
stage IV disease shows distant metastases 113.  Stage III/IV serous ovarian cancer is the most 
lethal and unfortunately the most common.   
In early stages, small OCs are typically difficult to detect and therefore OC is often 
discovered in the late stages when it has spread beyond the ovaries.  Current treatment 
consists of surgical removal of the tumor, hysterectomy, salpingo-oophorectomy, and 
omentectomy, followed by systemic chemotherapy. Specifically, the treatment involves 
aggressive tumor cytoreductive surgery followed by platinum- and taxane-based 
chemotherapy, with a response rate to first-line chemotherapy in approximately 65-80% of 
patients 114.  Unfortunately, most ovarian carcinomas relapse.  First-line chemotherapy with 
cisplatin and platinum is able to achieve complete remission in 65-80% of late stage OC 
patients but these treatments are ineffective in OC relapse, and drug resistance contributes to 
the comparatively low five-year survival rate. 
The central premise in OC immunotherapy is that tumor-associated antigen 
expression can be recognized by CTLs leading to tumor destruction 115, 116.  Examples of 
ovarian tumor antigens recognized by CTL include HER2, CA125, and MUC-1 117-122. 
These antigens have been incorporated into cancer vaccines currently in clinical trials 123-126, 
however clinical efficacy of these vaccines has exhibited only modest results.  CA-125 is the 
only marker approved for monitoring OC progression and treatment response, but it has a 
very low sensitivity for early stage OC and accounts for a high rate of false positive values 
127
.   
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Several other OC antigens have been identified, however, but which antigens are 
tumor rejection antigens is unknown (EGF receptor-derived peptide p971-980, FRα, IGFBP-
2, MUC16, p53, EpCAM, and some members of the CTA family).  Ioannides and his 
colleagues discovered CD8+ T cells, isolated from ovarian malignant ascites, capable of 
recognizing the human EGF receptor (EGFR)2 (HER-2/neu)-derived peptide, p971-980 128. 
HER-2/neu is an attractive immunologic target because of its low-level expression in 
peripheral tissues. However, the percentage of ovarian tumors with HER-2/neu expression 
has ranged from 5 to 66% 129-132, and data concerning the prognostic relevance of its gene 
amplification or protein overexpression in OC has been contradictory.  In another study, 
People and his colleagues found that tumor-associated lymphocytes isolated from the 
malignant ascites of OC patients recognized naturally processed and presented peptides 
derived from folate receptor (FRα) 133, 134.  It was also determined that FRα expression in 
nonmucinous ovarian tumors increased approximately 90-fold compared with normal 
epithelial cells 135.  Expression of FRα is limited to a few specific tissues such as the apical 
surface of kidney tubule epithelium 136.  Thus, FRα is a promising therapeutic target not only 
due to its tumor specificity and high-level expression, but also because it is naturally 
immunogenic.  However, there have been no follow-up reports confirming that FRα is an 
effective tumor-associated antigen.  Mutation in the p53 gene is one of the most common, 
single genetic alterations in sporadic human epithelial ovarian carcinoma 137.  As a result of 
mutation, p53 is overexpressed in nearly 50% of OCs.  However, in a recent 
immunotherapeutic study, small peptides derived from TP53 delivered in an emulsion-
adjuvant resulted in a weak T cell response and no tumor regression in advanced OC 
patients 138.   
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T cells in the tumor microenvironment are key players in patient outcomes.  T cell 
infiltration into ovarian tumors is associated with improved survival and in tumors with high 
numbers of tumor-infiltrating T lymphocyte cells (TILs), the expression of monokines 
induced by IFN-γ, macrophage-derived chemokines and secondary lymphoid-tissue 
chemokines, is significantly increased as compared with tumors lacking T cells 139.  Thus, 
the immune infiltrate has an active role in the clinical course of OC 139.  It has also been 
determined that there is improved survival in OC patients who have higher numbers of 
intraepithelial CD8+ T cells compared with patients without intraepithelial CD8+ T cells 140.  
A recent study shows a strong positive correlation between levels of CD8+ T cells and 
granzyme B within ovarian tumors, indicating that the majority of CD8+ T cells are 
cytotoxic 141.  Concerning CD4+ helper T-cell infiltration, Kryczek and colleagues found 
high levels of IL-17 associated with improved outcome suggesting that a subset of CD4+ Th 
cells, Th17 cells, have a role in eradicating ovarian tumors 142.  In another example, 
Tomosova and his colleagues have shown that patients exhibiting higher CD3+ TIL cell 
numbers had an improved overall survival than those patients with lower CD3+ cell numbers 
143
.  These conclusions provide possible insight needed for further immune therapies 
designed to influence recruitment of helpful T cell subsets.  
1.8  Immune suppression and microenvironment in ovarian cancer 
A major reason for the current lack of effective immune-based treatments is that 
ovarian tumors establish a complex multilayered immune suppression network which 
suppresses any antitumor efforts 144.  There are several mechanisms by which tumors can 
arrest the immune response.  First, tumors can increase the numbers of T regulatory cells (T-
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regs) in the peripheral blood of OC patients 145.  Secondly, tumors can recruit or induce T-
reg tumor infiltration.  Indeed, a study by Curiel and his colleagues demonstrated that the 
accumulation of intratumoral T-regs was associated with a high mortality rate 146.   
As mentioned previously, it is believed that the presence or absence of specific 
populations of T cells within epithelial OC tumors is associated with important differences 
in prognosis.  Importantly, the detection of antitumor immune response in the form of 
intraepithelial tumor infiltrating lymphocytes (TILs) predicts significantly longer survival in 
OC 139.   Alternatively, the presence of T-regs in ovarian tumors has been associated with 
reduced overall survival 146, 147.  Indeed,  Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, 
Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, 
Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, and 
Zou W found evidence that CD4+CD25+FOXP3+ regulatory T cells in patients with ovarian 
carcinoma suppress tumor-specific T-cell immunity and contribute to growth of human 
tumors in vivo 146.   Also, the presence of T-regs was found in OC ascites but not in normal 
ascites 148.  This insinuates that T-reg depletion can possibly become a promising strategy 
for boosting TAA-specific immunity149.   
Vaccines have been the main approach to OC immunotherapy 108, 146, 150, 151, however 
much work is needed to improved their performance.  Depletion of T-regs is a critical 
maneuver to enhance vaccine therapy.  To test this, a pilot study at the University of 
Pennsylvania is currently administering partially mature dendritic cells (DCs) pulsed with 
autologous tumor cell lysate to subjects with recurrent OC in combination with immune 
modulation with oral metronomic cyclophosphamide (to deplete T-regs) and bevacizumab 
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(to disrupt the blood tumor endothelial barrier) 152; partial objective responses have been 
observed. 
In addition to infiltration by T-regs, expression of the negative regulatory co-receptor 
B7-H1 by tumor cells and infiltrating myeloid DCs, expression of B7-H4 by tumor-
associated macrophages, and expression of indoleamine 2,3-dioxygenase (IDO) all correlate 
with increased morbidity and mortality in OC.  Strategies for depletion of myeloid 
suppressor cells, blockade of B7-H1 signaling, or inhibition of IDO activity are all currently 
under investigation as free-standing treatments or adjuvants for active immunotherapy for 
OC 153.  Overcoming suppressive mechanisms found within the tumor microenvironment in 
order to enhance efficacy is a major challenge for current approaches to cancer vaccination.   
Recent studies have determined that the immune system plays a critical role in 
controlling growth and spread of ovarian tumors and therefore it is critical for future 
immunotherapies to overcome these immune inhibitory mechanisms.  Various studies have 
shown that OC escapes immune surveillance with high efficiency via creating a tolerogenic 
microenvironment.  OC-infiltrating plasmacytoid DC and macrophages produce the 
chemokine CCL22 which acts via CCL4 expressed by Th2 cells154, memory T cells 155 and 
regulatory T cells 156.  High levels of CCL22 have been detected in OC ascites and OC but 
not in normal ovaries 146.  This group specifically found that CCL22 expression in the tumor 
microenvironment triggers T-reg migration into the tumor lesion.  They also determined that 
CD4+CD25+FoxP3+ T-regs suppress tumor-specific T-cell immune responses in OC 
patients, thus promoting tumor growth in vivo, and that tumor T-reg infiltration is correlated 
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with reduced survival 146.  This indicates that OC tumor progression exploits different types 
of mechanisms to hamper the immune response and evade immune surveillance.   
Limited success of cancer vaccines are also due to other negative influences in the 
tumor microenvironment.  One particular example pertains to the lack of T-cell 
costimulatory molecules in most solid tumors.  This results in activated T cells becoming 
anergized and loosing lytic capacity.  It has also been shown in preclinical models of chronic 
viral infection that T cells chronically exposed to viral antigen can become exhausted 157, 158. 
Interstitial pressure within a large tumor mass is another negative influence as it diminishes 
diffusion of macromolecules such as antibodies and T cells 159, 160.  Also, T-reg, tumor cells, 
and other cells in the tumor microenvironment have the potential to release soluble 
immunosuppressive factors including TGF-β, IL-10, indoleaimine-pyrrole 2,3 dioxygenase 
(IDO) and VEGF 161-163.  Finally, the phenotype of tumors also has the potential to change as 
seen with the tendency for IL-8 to drive carcinoma cells to the EMT phenotype 164.   
Many tumors display antigenic heterogeneity at both the level of antigen expression 
and at the level of the antigen-peptide MHC complex 165.  Defects in MHC-peptide 
complexing machinery has also been detected in tumor cells 166-170.  An example of this was 
seen when cloned carcinoma cells reverted to express a more heterogenous antigenic 
population upon passage.  This phenomenon has also been witnessed in clinical trials in 
which vaccinated patients develop higher levels of T cell responses to tumor-associated 
antigens compared to the antigen in the vaccine 171-173.  
As stated above, recent studies have identified a survival advantage associated 
specifically with the presence of intraepithelial TILs, located in specific tumor islets 174.  
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The intraepithelial TILs in OC specimens are a robust biomarker for overall survival of 
women with this disease. If validated, TIL scores could be used not only to select women for 
clinical trials of cancer vaccines or adoptive T cell therapies, but could also be used to select 
combinations of chemotherapeutic drugs that interact positively with antitumor immune 
mechanisms174.  
1.9  Involvement of HERV-K in Ovarian Cancer 
In a keystone 2006 paper from our laboratory, we turned our focus to another 
perilous female cancer and produced cogent results demonstrating expression of multiple 
HERV-K SU env proteins in OC.  We also showed that in contrast to most cancers which 
express 1 or 2 HERVs, at least three HERV env genes were expressed in OC, including 
HERV-K Types 1 and 2, ERV3, and HERV-E 175.  Specifically, Type 1 (1,105 bp) and Type 
II (1,195 bp) HERV-K surface domains were detected at a higher frequency in established 
OC cell lines compared to normal epithelial cells or immortalized normal ovarian cell lines.  
Also in this study, expression of HERV-K env mRNA was greater in ovarian epithelial 
tumors compared to normal ovarian tissues (n=254).  We also determined both cytoplasmic 
and cell surface expression of HERV-K env protein in established OC cell lines but not in 
immortalized normal ovarian cell lines.  FACS analysis further confirmed cell surface 
expression by revealing greater surface expression of HERV-K env protein on established 
OC cell lines but not in immortalized normal ovarian cell lines.  We also confirmed HERV-
K SU env protein expression in ovarian tumor epithelial cells and correlated this significant 
increase with tumor histotype.  Finally, we ascertained that 55% of OC patient samples 
(n=60) had positive titers for anti-HERV-K antibodies compared to only 5% of normal 
female controls (n=20).     
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Upon publication of this study, we were the first to report that HERV-K env protein 
was expressed on the surface and in the cytoplasm of HERV-K-positive OC cells.  Most 
importantly, no expression was detected in normal or immortalized normal or immortalized 
normal surface ovarian epithelial cells.  The detection of anti-HERV-K antibodies in OC 
patient sera samples showed a lack of tolerance and confirmed that OC patients possessed 
the ability to mount an immune response against specific HERVs.   
 
1.10  Mechanisms by which HERV-K is selectively expressed in ovarian cancer 
The majority of HERV insertions are transcriptionally silenced in most embryonic 
and adult tissues through repressive epigenetic marks 176 that are deposited and maintained 
by the host surveillance system 177.  Failure to maintain these marks results in the 
reactivation of dormant HERV insertions 178.  Dysregulated expression of HERVs may be 
related to hypomethylation of HERV genes in tumor cells 179, 180, therefore the repressive 
role of DNA methylation on HERV activity in human cells and tissues is being increasingly 
studied.  Epigenetic aberrations, including genome-wide hypomethylation, are crucial in the 
development and progression of OC 181.   In contrast to the overall DNA methylation 
patterns observed in normal cells, a global hypomethylation of CpG dinucleotides in 
combination with hypermethylation of CpG islands occurs in cancer 182.  CpG islands tend 
to associate with the promoters of housekeeping genes 183 and therefore their methylation in 
malignancy causes repression of tumor suppressor genes 184.  In contrast, DNA 
hypomethylation renders HERVs transcriptionally active 10.  HERV-K hypomethylation can 
lead to several biological consequences including genomic instability 185, 186, aberrant gene 
expression due to effects from LTRs 187, and cancer development via HERV RNA or 
29 
proteins.  Selective transcription of HERV-K could be explained by changes in tumor-
specific transcription factors or tissue specific factors 188-190.  Activation could also be 
attributable to selective hypomethylation of these genes as seen with HERV-W in human 
OC 180, 191, 192.   
The expressions of HERV-K and HERV-E are increased in tissues from patients 
with ovarian clear cell carcinoma (OCCC), a particular type of epithelial OC.  Long 
interspersed repetitive sequence-1 (LINE-1), a specific type of intersperse repetitive 
sequence (IRS), is hypomethylated in most cancers including epithelial OC 193, 194.    
Therefore in a recent study, Iramaneerat K, Rattanatunyong P, Khemapech N, Triratanachat 
S, Mutirangura A evaluated if the loss of DNA methylation of HERV sequences can be an 
epigenetic signature to predict the prognosis and treatment response of OCCC 195.  Indeed 
they found that both HERV-K and HERV-E lose methylation during OCCC progression and 
only HERV-K hypomethylation is significantly associated with poor survival and platinum 
resistance195.  Determining HERV-K methylation levels in OC before chemotherapy may be 
critical for proper treatment plans in the future.  Further studies must be conducted in order 
to determine the mechanisms involved in HERV-K hypomethylation. 
 
1.11  Mounting effective antitumor immunity 
 There are three distinct steps that must be achieved in order to mount effective 
antitumor immunity.  First, to initiate immunity, DCs must sample antigens derived from the 
tumor such as mutated proteins typical of cancer, the products of non-mutated genes that are 
preferentially expressed by cancer cells, or differentiation antigens associated with the 
cancer’s tissue of origin 196, 197.  Within the realm of therapeutic vaccines, these antigens are 
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delivered exogenously.  When a DC ingests this antigen, it will also require an activation 
signal to differentiate and promote immunity 198, 199.  
Secondly, tumor-antigen loaded DCs must generate protective T-cell responses in 
lymphoid organs 200.  The specific type of T-cell response needed for antitumor immunity is 
unknown.  However, it will unquestionably include CD8+ effector T cells with cytotoxic 
potential.  It is imperative that the DCs received the maturation signal at this point in order 
to elicit the desired T cells, otherwise un-matured DCs promote tolerance by T-reg 
production 201-204.   
Finally, cancer-specific T cells must enter the tumor bed to perform their function.  
Due to the complex tumor microenvironment, this step in antitumor immunity is a key 
challenge.  One major obstacle is local accumulation of T-regs that oppose the activity of 
effector T cells.  Tumors also have the ability to down-regulate their expression of MHC 
class I molecules or their expression of target tumor antigens.  Additionally, tumors can 
produce surface molecules that engage receptors on the surfaces of activated T cells, causing 
T-cell anergy or exhaustion 205, 206.  Tumors can also release immunosuppressive molecules 
limiting T-cell function 207, 208.  Hypoxia in the tumor microenvironment may also inhibit T-
cell function via the generation of adenosine 209.  Finally, tumor stroma cells can suppress 
the functions of T-cells by several methods 210.   
 
1.12  Immunotherapy 
Immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an 
immune response.  There are two types of manipulation based on the functionality of the 
patient’s immune system.  If the patient’s immune system is functional, immunotherapy can 
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be use d to activate or enhance the patients’ immune system via exposing patients to tumor-
associated antigens displayed by their tumors.  If the patient’s immune system is not 
functional, passive immunization via introduction of antibodies or adoptive transfer of 
immune cells needs to be employed.   Cancer immunotherapy combines the specificity of 
the adaptive immune system with the cytotoxic capabilities of both the adaptive and innate 
immune systems.  Immunotherapy strategies include the following:  antitumor monoclonal 
antibodies, cancer vaccines, adoptive transfer of ex vivo activated T and natural killer cells, 
and administration of antibodies or recombinant proteins with the potential to either 
costimulate immune cells or block immune inhibitory pathways 211.  
Tumor-specific monoclonal antibodies (mAb) have had a major impact on 
immunotherapy. Numerous mAbs, including bispecific mAbs and multispecific fusion 
proteins, mAbs conjugated with small-molecule drugs, and mAbs with optimized 
pharmacokinetics, are in clinical trials.  Importantly, it is the interaction between mAb and 
Fc receptor (FcR) that contributes to the clinical antitumor activity of mAbs.  For example, 
changing the sequence or glycosylation of Fc regions can enhance interactions with FcR in 
immune effector cells 212, 213.  There are extensive interactions among various mechanisms 
of action that modulate the immune effects of mAbs.  Many studies have shown data 
supporting the role of antibody-dependent cell-mediated cytotoxicity (ADCC) as a major 
mechanism of mAb activity. Complement-mediated cytotoxicity (CMC) may contribute to 
antitumor activity in solid tumors but there is little evidence.  MAbs have shown great 
promise and are currently the three top-selling cancer drugs.  The majority of mAbs 
approved for clinical used contain a human immunoglobulin (Ig) G1 heavy chain. 
Trastuzumab is a recombinant humanized mAb that targets the HER2 receptor, inhibits cell 
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proliferation and DNA repair, induces apoptosis, and promotes DNA damage and immune 
modulation, thus causing cell-cycle arrest.  This mAb has been approved by the US FDA for 
the treatment of metastatic BC with HER2 overexpression.  Cetuximab is a chimeric mAb 
raised against epidermal growth factor receptor (EGFR) and inhibits endogenous ligands 
binding, cell motility, invasiveness, metastasis, and the promotion of apoptosis 214.  
Cetuximab is also FDA approved for treating advanced colorectal cancer and squamous cell 
carcinoma of the head and neck.  Bevacizumab is a humanized mAb that inhibits the 
biological activities of vascular endothelial growth factor (VEGF) and blocks binding of 
VEGF to its receptor on vascular endothelium.  This mAb has been FDA approved since 
2004 as first-line therapy in metastatic colorectal cancer. 
The beauty of cancer vaccines is that they demonstrate minimal toxicity in 
comparison to other forms of cancer therapy which kill tumor cells and normal cells alike.  
However, the success of immunotherapy depends on overcoming several significant 
barriers.  First, tumor-associated antigens are typically closely related or identical to self-
antigens, making unwanted autoimmune responses a risk.  Secondly, the 
immunosuppressive factors within the tumor microenvironment need to be avoided 215.   
The idea of a therapeutic cancer vaccine originated with the discovery that patients 
produce CD8+ and CD4+ T cells specific for antigens expressed in their tumors 196.  
Common tumor-associated antigens include oncoproteins, oncofetal antigens, 
differentiation-associated protein, viral proteins, and others.  The goal of vaccination was 
therefore to amplify the frequency and strength of these responses or induce new reactions.  
Studies have shown a strong association between the presence of intratumoral CD3+ or 
CD8+ cytotoxic T cells and the IFN-γ gene signature and prolonged patient survival 139, 216.  
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This idea was an expedient one, however many initial attempts failed due to a poor 
understanding of the immune system.  Presently, the importance and function of DCs has 
been determined to play a key role in improving therapeutic efficacy.  A recent study of 
peptides derived from the HPV-16 E6 and E7 viral oncoproteins showed clinical responses 
in women with vulvar intraepithelial neoplasia due to the presence of HPV-specific IFN-γ-
producing CD4+ and CD8+ T cells 217.   It is believed that these propitious results are due to 
the fact that viral proteins are recognized as foreign by the host, leading to a stronger T-cell 
response.  
In comparison to peptides, full-length proteins contain a broader profile of epitopes 
that might be presented by DCs and therefore may be more advantageous.  It is known that 
for a cancer vaccine to be efficacious, it must induce both antigen-specific CD8+ CTLs and 
antigen-specific CD4+ cells, and protein-based vaccines usually contain both 165.  Indeed, a 
current randomize phase III trial using a recombinant fusion protein, MAGE-A3, an 
adjuvant, and TLR4 and TLR9 agonists, has shown a survival response of 27% in HLA-A2-
positive non-small cell lung cancer patients 218. 
Another vaccination strategy under evaluation involves viral vectors encoding tumor 
antigens.  These strategies exploit the fact that viral components elicit strong immune 
responses. In a current phase II trial, recombinant vaccinia virus encoding prostate-specific 
antigen and the adhesion molecules B7-1, ICAM-1 and LFA-3, were combined with GM-
CSF to produce a vaccine against prostate cancer.  Positive results indicate an overall 
survival benefit of 25.1 months versus 16.6 months in the control group 219.   
Numerous preclinical studies have presented data on the enhanced antitumor 
responses seen when vaccines are combined with inhibitors of immune suppression.  
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Monoclonal anti-CD25-diptherial toxin (Ontak) has been shown to successfully reduce T-
regs and to enhance vaccine efficiency 220, 221. Cyclophosphamide also reduces the number 
of T-regs and their functionality, and has been shown to enhance vaccine efficacy in both 
preclinical and clinical studies 222, 223.  Both monoclonal and small molecule inhibitors to 
TGF-β may have potential in vaccine combination therapy  224-227. 
1.13  Stem cells in ovarian cancer 
Cancer stem cells are rare chemotherapy resistant cells within a tumor which can 
serve to populate the bulk of the tumor with more differentiated daughter cells and 
potentially contribute to recurrent disease 228.  Within an OC, there are many unique cell 
populations that each have different capacities for growth, survival, metastasis and 
resistance to chemotherapy and radiation therapy 229, 230, however the exact phenotype and 
characteristics of OC stem cells are still disputable 231.  Cancer stem cells typically make up 
0.01-1.0% of malignant cells within a tumor and have unlimited division potential.  Based 
on their resistance to traditional cancer therapies and presumed ability to recapitulate the 
original tumor, cancer stem cells are believed to be the source of recurrent OC 228.  
Therefore much effort  has been given the characterization of these stem cells in order to 
ultimately target them.  One of the most widely known OC stem cell markers is CD133, a 
membrane glycoprotein encoded by the CD133/Prom-1 gene. In a keystone article, 
Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli 
E, Rutella S, Paglia A, Zannoni G, Mancuso S, and Scambia G determined that primary OC 
CD133+ cells had greater colony forming potential and higher proliferative potential than 
CD133- cells 232.  More importantly, they determined that normal ovaries and benign tumors 
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had a significantly lower expression of CD133 than ovarian carcinomas.  CD44, a receptor 
for hyaluronic acid, has been identified as a marker of cancer stem cells in breast 233, 
prostate 234, colorectal 235, pancreatic 236, head and neck squamous cell carcinomas 237.  One 
study analyzed tumor spheroids generated from the ascites of patients with serous ovarian 
cancer 238.  After ~10 serial passages in stem cell media, it was observed that the remaining 
spheroid cells were highly enriched for CD44 expression, were resistant to chemotherapy, 
and were able to initiate and serially propagate tumors in mice.  These stem cells markers 
represent potential therapeutic targets and may even be functionally important for stem cell 
survival, making them even more attractive.  One downside is that only 34-40% of ovarian 
tumors express CD133 230, 232, 239.  Also, CD44 may have a broad expression including 
normal tissue.  Therefore, targeting these stem cells with other types of tumor specific 
markers has the potential to lead to localized therapeutic approaches but minimization of 
systemic exposure needs to be optimized.  
1.14  Project Overview 
In our previous work, we were the first report expression of HERV-K env protein in 
actual specimens of breast ductal epithelial tumors but not in normal breast in humans.  We 
also determined that HERV-K has great potential as a BC vaccine because it induced an 
antigen-specific immune response in BC patients.  Specifically, we showed that cytotoxic T 
lymphocytes from cancer patients could lyse established BC cell lines expressing HERV-K.  
At that time, only one other group had documented the presence of HERV-K-specific CTL 
responses in human cancer 80.  We then delved into another malevolent female cancer, OC, 
and were the first to report that HERV-K env protein is expressed on the surface and in the 
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cytoplasm of OC cells and that expression of HERV-K env mRNA was greater in ovarian 
epithelial tumors than in normal ovarian tissues.  Additionally, we confirmed that the 
frequency of expression of HERV-K env protein in OC samples had a significant correlation 
with tumor histotype.  Finally we detected anti-HERV antibodies in patients with OC, but 
not in normal female controls. 
Based on our previous findings in BC and OC, our next goal was to reconfirm 
HERV-K expression in OC and evaluate the effectiveness of HERV-K as a potential tumor-
associated antigen  for development of an OC vaccine by examining a new patient cohort 
which included samples from OC patients, patients with benign disease and adjacent 
uninvolved samples.  We obtained several patients providing both tumor and adjacent 
uninvolved samples, allowing an ideal situation to determine differences in HERV-K env 
expression patterns and immune responses.  Most importantly, we wanted to determine if 
cytotoxic T cells from cancer patients could lyse autologous target cancer cells expressing 
HERV-K while ignoring normal cells.  Therefore, we hypothesize that HERV-K is a tumor-
associated antigen and that there is selective expression and distribution of these elements in 
OC, but not in benign samples or normal controls.  We hypothesize that HERV-K env 
protein, a retroviral antigen product, will be a safe and efficient candidate for development 
of an OC vaccine. 
Our first aim is to assess the expression profiles of HERV-K env proteins and anti-
HERV-K antibodies in primary OC, benign patient samples, and normal controls. To 
achieve this goal we utilized a new patient cohort and determine expression of HERV-K env 
mRNA and protein. We specifically determined cell surface expression of HERV-K env 
37 
protein in primary samples from OC, benign and adjacent uninvolved tissues. We then 
characterized the primary cells based on IF expression and stem cell markers.  Next we 
assessed whether activation of HERV-K correlates with clinical or histological 
characteristics of OC patients.  We also determined and compared levels of anti-HERV-K 
Abs in OC and benign patient serum samples and correlated them with clinical 
characteristics.   
Our second aim is to evaluate the immune responses triggered by HERV-K antigen 
in OC, benign patient, and normal donors. To achieve this we first characterized patient 
samples to determine specific lymphocyte populations. Next, we determined changes in T 
cell proliferation and IFN-γ secretion in OC patient lymphocytes compared to benign 
samples, and normal donors. We also determined CTL activity using autologous OC, 
benign, and adjacent uninvolved patient target cells.  Finally we determined the effects T-reg 
depletion on CTL activity.  
The majority of current tumor-associated antigens represent self-antigens that have 
become aberrantly expressed by the cancer.  Therefore, the majority of solid tumors are not 
immunogenic.  Also, these antigens are sometimes expressed in normal tissues.  Thus 
immunotherapeutic techniques targeted against these antigens are impeded by the need to 
overcome self-tolerance mechanisms that ultimately limit the immune response.  Viral 
antigens, on the other hand, are considered “foreign” to the body and might elicit stronger 
antitumor T-cell responses.  Therefore we believe that HERV-K, a novel tumor-associated 
antigen, is an ideal target for immunotherapy in OC.   
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Chapter 2.  Materials and Methods 
2.1  Human primary samples 
Human ovarian tissues and peripheral blood mononuclear cells (PBMC) from OC 
patients, patients with benign disease, patients with other cancers, or healthy female controls 
were obtained from The MD Anderson Cancer Center according to approved Institutional 
Review Board protocols.  Age distribution and patient histological diagnoses are shown in 
Figure 4. 
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Figure 4:  Ovarian patient age distribution.  The age distribution of patients used in this 
study. 
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Figure 5:  Ovarian histological diagnoses distributions. Examples from each histological 
category are listed.  Surface epithelial tumors: papillary serous carcinoma, serous borderline, 
Mullerian borderline tumor, metastatic adenocarcinoma, mucinous adenocarcinoma.  Germ 
cell tumors:  teratoma.  Benign disease: endometriotic cyst, benign cyst, follicular cysts.  
Other cancer: gastrointestinal stromal tumor, neuroendocrine tumor, gallbladder 
adenocarcinoma.  Other: endometriosis, fibrotic tissue with inflammation.  
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2.2  Established cell lines 
OVCAR3, SKOV3, DOV13 human epithelial OC established cell lines were 
obtained from ATCC (Rockville, MD).  Cells were grown in Dulbecco’s modified eagle 
media (DMEM) supplemented with 10% FBS, 1% penicillin-streptomycin and 1% 
Glutamax. 
 
2.3  Harvesting of primary tissue samples 
A piece of tissue in 1-2 ml of cold complete NOE culture medium (250 ml of 
Medium 199+ 250 ml DMEM) supplemented with 10% FBS, 1% penicillin-streptomycin 
and 1% Glutamax, was added to a Petri dish and chopped into small pieces with a razor 
blade to obtain a thick soup of tumor cells/pieces.  20X the volume of cold medium was 
added, inverted to mix, and spun at 900 rpm for 5 minutes.  The tissue pieces and 
dissociated cells pelleted, while the debris remained in the supernatant.  The supernatant was 
removed and the cells were resuspended in Accumax solution at a concentration of 10 
ml/0.5 g of tissue and incubated at room temperature for 60 minutes on a shaker.  The cells 
were washed with 1xPBS, resuspended in 20 ml of media, and transferred to a Stomacher 80 
bag.  The bag was inserted into the Stomacher (Seward Co.) and run for 15 minutes at high 
speed.  The mixture was transferred to a 50 ml tube and the larger chunks were allowed to 
settle to the bottom.  The supernatant containing the dissociated cells was transferred to a 
fresh tube, spun at 900 rpm for 5 minutes, and resuspended in 1-3 ml medium.  The cells 
were then passed through a 40µm nylon mesh into a 50 ml tube.  The live cells were then 
separated from dead cells, debris, and red blood cells via the use of a Ficoll-1077 gradient.  
The cells were spun on Ficoll-1077 at 400g for 30 minutes at room temperature and the 
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opaque layer of cells at the interphase of the two layers was transferred to a new tube.  The 
cells were spun at 900 rpm for 5 minutes, resuspended in low serum NOE media to and 
plated in a 6-well low adherent plate.  To culture tumorspheres, 6-well plates were coated 
with 1 ml of 0.8% agarose 240, and cells were added in 2 ml per well of Mammocult media 
supplemented with heparin and hydrocortisone. 
 
2.4  RT-PCR  
For tissue samples obtained at the MD Anderson Cancer Center, RNA isolation and RT-
PCR were employed as described previously 67, 68.  Briefly, total RNA was isolated from 
primary cell lines in Tri-reagent according to the manufacturer’s instructions and treated 
with RNase-free DNase I at 37°C for 30 minutes to prevent contamination of genomic DNA. 
RNA was then incubated at 75°C for 5 minutes to inactivate residual DNase.  A first strand 
cDNA was synthesized from the RNA template using Ready-To-GoTM You-Prime First-
Strand Beads.  10µg RNA was added to 32µl of diethylpyrocarbonate (DEPC)-treated H2O 
and incubated at 65°C for 10 minutes.  Following this incubation, 1 µl of random primers 
were added to the RNA solution and then incubated again with the beads at 37°C for 1 hour.  
3.3µl of cDNA, corresponding to 1 µg of RNA, was incubated with 5 µl of 10x PCR buffer, 
0.25 µl of Taq DNA polymerase, and the various primer pairs.  Primers used for RT-PCR 
included HERV-K SU env type 1 and type 2 primers, HERV-E env primers, ERV-3 primers, 
and β-actin primers, which were described previously 175. No template and β-actin were used 
as negative and positive controls, respectively.  The HERV-K env PCR primers were 
designed by Sangon Biotech Co. Ltd. (Shanghai), and produced by Takara Biotechnology 
Co. Ltd. (Dalian), according to the HERV-K102 env sequence (GenBank accession no. 
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AF164610.1).   After the initial denaturation step at 94°C for 3 minutes, 30 cycles of 
amplification were performed as follows: denaturation at 94°C for 1 minute,  annealing at 
55°C for 1 minutes, and extension at 72°C for 1 minute.  The RT-PCR product was then 
subjected to electrophoresis on a 1% agarose gel by ethidium bromide staining to confirm 
size.   
 
2.5  Synthesis of HERV-K env fusion proteins and antibodies and cRNA 
HERV-K env surface fusion proteins were expressed from the pGEX-6p1 plasmid 
(K10G17) in Escherichia coli (E.coli) BL-21(DE3) or from the pQE30 plasmid (K10Q18) in 
E. coli M15 by incubating at 18°C overnight in the presence of ampicillin (100 µg/ml), 
kanamycin (25 µg/ml), and 1 mmol/L isopropyl-L-thio-B-D-galactopyranoside until an 
OD600 of 0.8 was reached.  To express the TM fusion protein, a recombinant pQE30-TM 
bacterial clone was grown in an identical manner.   Bacterial pellets were harvested, 
disrupted by lysozyme treatment followed by sonication, clarified by 0.2 µm filtration, and 
affinity purified with glutathione-Sepharose FF using an ÄKTA fast protein liquid 
chromatography (FPLC; GE Healthcare). The purified K10Q18 fusion proteins were then 
used to immunize 6- to 8-week-old BALB/c mice.  Hybridoma cells were derived from the 
splenocytes of immunized mice by fusion with a myeloma cell line using standard 
techniques, as described previously 175, 241. Several monoclonal antibodies against HERV-K 
env SU protein were generated in our laboratory and ELISA and immunoblot screening 
revealed that mAb 6H5 had the highest specificity and sensitivity toward HERV-K.  6H5 
hybridoma ascites was then collected from pristane-primed mice, precipitated twice with 
saturated ammonium sulfate, clarified by 0.2 µm filtration, and affinity purified with protein 
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G-Sepharose HP by FPLC. The eluate fractions containing 6H5 mAb were dialyzed against 
PBS, concentrated, and filter sterilized before testing.   6H5 antibody was labeled with Alexa 
Fluor® dyes 647 and 488 to be used in FACS analysis and IFS respectively.  Keyhole limpet 
hemocyanin (KLH) protein (Pierce) was used as a negative control throughout our 
experiments. Several experiments utilized the human papillomavirus E6 protein as a 
negative control.  HERV-K and E6 cRNA were produced by in vitro transcription 67. 
 
2.6  ELISA 
100 µl of diluted KSU protein (10 µg/ml) was added to each well of a flat-bottom 96 
well plate, and incubated overnight at 4°C.  Plates were washed 6 times with 1xPBS, 100 µl 
of blocking buffer (1xPBS+1% BSA) was added to each well, and plates were incubated at 
room temperature for 60 minutes.  Blocking buffer was removed by flipping the plate over 
and tapping it on a paper towel.  E. coli lysate was added to serum samples at a 1:20 dilution 
and the mixture was incubated for 30 minutes at room temperature.  Human patient serum 
was then added in the correct dilution to triplicate wells and plates were incubated overnight 
at 4°C.  Plates were washed 6 times with 1xPBS, 100 µl of mouse-IgG-HRP (1:4,000 
dilution in 1xPBS) secondary antibody was added to each well and incubated for 60 minutes 
at room temperature.  Plates were again washed 6 times with 1xPBS and 100 µl of ABTS 
substrate solution (200 µl ABTS and 10 µl 30% H2O2 in 10 ml citrate buffer) was added to 
each well.  The absorbance was measured with a Wallac VICTOR2 plate reader (Perkin 
Elmer) at 405 nanometers at different time points. The ELISA was performed in triplicate 
for each dilution. 
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2.7  FACS 
1 x 106 cells/well were added to a round-bottomed 96-well plate and labeled with 1 
µg/well of primary antibody diluted in BD Stain Buffer (BD Biosciences) for 60 minutes at 
room temperature. After washing cells twice with 1xPBS, samples were incubated with 
secondary Alexa Fluor 647 conjugated mouse-IgG for 30 minutes at room temperature.  
After washing cells twice with 1xPBS, samples were resuspended in 250 µl 1xPBS and 
analyzed by a BD FACsArray (BD Biosciences). 
 
2.8  QIFIKIT 
QIFIKIT (Dako) was used for the quantitative determination of cell surface HERV-K 
antigen by flow cytometry using an indirect immunofluorescence assay.  1 x 106 human 
patient ovarian cells/well were added to a round-bottomed 96-well plate and labeled with 
6H5 mAb at saturating concentration.  The cells were incubated, in parallel with the 
QIFIKIT® beads, with secondary Alexa Fluor 647 conjugated mouse IgG at saturating 
concentration. A calibration curve was constructed by plotting the fluorescence intensity of 
the individual bead populations against the number of mAb molecules on the beads. The 
number of antigenic sites on the specimen cells was then determined by interpolation. 
 
2.9  Immunofluorescence (IFS)/Fluorescence Microscopy/Confocal Microscopy 
5x105 cells/well were seeded onto glass coverslips in a 6-well plate and incubated at 
37°C overnight.  The media was removed and cells were fixed with fresh 4% 
paraformaldehyde for 20 minutes at room temperature.  Cells were blocked in 3% BSA 
blocking buffer for 60 minutes at room temperature, and then incubated with primary 
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antibody for 60 minutes at 37°C.   After washing cells twice with 1xPBS, samples were 
incubated with secondary Alexa Fluor 488 conjugated mouse IgG for 30 minutes at 37°C.  
After washing cells twice with 1xPBS, cellular nuclei were stained with DAPI for 3 minutes 
at room temperature, and then washed again with deionized H2O. Coverslips were added to 
the slides with 90% glycerol in water and examined under either an Olympus IX51 
fluorescent microscope with a DP70 camera, or a laser-scanning confocal microscope (Zeiss 
510 Meta) with appropriate filters. 
 
2.10  Immunohistochemical analysis (IHC) 
Immunohistochemical analysis was performed on tissue slides using an LV-1 
Autostainer universal staining system (Dako) in combination with the VECTASTAIN ABC 
system and DAB kit (Vector).  Slides were baked in an oven at 60ºC for 1 hour and then 
removed to cool.  Slides were placed on an Autostainer to deparaffinize and hydrate tissue 
sections through xylenes and a graded alcohol series.  A circle was drawn with a wax pencil 
around the section of tissue.  Peroxidase blocking solution (3% H2O2) was added to each 
slide and incubated at room temperature for 10 minutes.  The slides were washed for 5 
minutes in H2O.  Blocking solution was added (AB serum (2% solution in 1XPBS), goat 
serum (2% solution in 1XPBS plus 3% BSA) to slides and incubated at room temperature 
for 30 minutes.  The solution was tipped off without rinsing and 150 µl of diluted 6H5 mAb 
in 1 ml of blocking solution was added to each section.  The slides were placed into a 
humidified chamber and place in a 4ºC cold room for 16 hour.   Slides were washed three 
times with 1XPBS for 30 minutes each in a glass container with a stir bar.  Sections were 
incubated for 30 minutes with mouse-IgG-HRP (1:600 dilution in blocking buffer) 
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secondary antibody and then washed three times with 1XPBS for 30 minutes each in a glass 
container with a stir bar.  Sections were incubated in DAB for 5 minutes and then washed in 
H20 to stop the DAB reaction.  Slides were counterstained with hematoxylin for 8 minutes, 
washed thoroughly in H20, and placed in the Autostainer through a graded alcohol series and 
xylenes.  Cover slips were added with Permount, and samples were examined under a 
microscope Axiovert 200 (Carl Zeiss MicroImaging, Thornwood, NY). 
 
2.11  Peripheral blood mononuclear cell (PBMC) isolation from human blood samples 
PBMCs were isolated from whole blood samples by density gradient 
centrifugation using Ficoll-1077 (Sigma, St. Louis, MO). Briefly, 10 ml of blood from a red 
Vaccutainer tube was spun down at 2,000 rpm for 5 minutes at room temperature, and the 
serum layer was removed and stored at -80°C for future analysis.  10 ml of blood from a 
sodium heparin green Vaccutainer tube was transferred to a 50 ml Falcon tube and spun 
down at 2,000 rpm for 5 minutes at room temperature. The upper plasma layer was removed 
and stored at -80°C for future analysis. 1xPBS was added to the remaining blood to reach a 
final volume of 40 ml.  The diluted blood was then very slowly added to a 50 ml Falcon tube 
previously loaded with 10 ml Ficoll-1077.  The tubes were spun down at 1,500 rpm for 30 
minutes at room temperature using slow acceleration and deceleration rates.   PBMCs were 
recovered by collecting the Ficol-1077 and 1xPBS layers without disturbing the pellet of 
erythrocytes and granulocytes and placing them in a new 50 ml tube. The cells were washed 
by adding 30 ml PBS and spun down at 2,000 rpm for 10 minutes at room temperature. The 
supernatant was discarded, 5 ml of RBC Lysis Solution (8.3g NH4Cl, 1.0g KHCO3, and 1.8 
ml of 5% EDTA in 1L distilled H2O) was added to the cells and the mixture was incubated 
for 5 minutes at room temperature. After washing three times with
resuspended in complete RPMI 1640 culture medium at
and placed in a 37°C incubator overnight for
 
2.12  Preparation of dendritic 
PBMCs were plated at a density of 2x10
for 16 hours at 37°C.  Warm media was carefully added and used to wash the cells 
times.  The non-adherent cells were 
remaining adherent cells were incubated
stimulating factor (GM-CSF) and in
immature DCs were harvested and transfected with K
BioPORTER lipid-based transfection reagent per the manufacturer’s 
hours, tumor necrosis factor-
induce DC maturation.  
 
2.13  Preparation of IVS cells 
PBMCs (1 x 106/ml) were added to 
DC at a DC to PBMC ratio of 1:30 on day 0. Cultures
supplemented with 5% human Ab serum and
week IVS cells.  
 
 
 
48 
 1xPBS, the PBMCs were 
 2×106/ml, seeded in a 6
 DC preparation. 
cells 
6
 cells/well in a 6-well plate and incubated 
pelleted and frozen back for future assays. 
 for 6 days with granulocyte macrophage colony
terleukin (IL)-4 (1,000 units/ml) (R&D Systems). The 
-SU or KLH protein using the
instructions.  After four 
 (TNF- ) (1,000 units/ml) was added for 16 hours at 37°C
 
autologous HERV-K protein transfected 
 were cultured in AIM V medium 
 IL-2 (100 units/ml) for 7 days 
-well plate, 
three 
 The 
-
 
 to 
matured 
to generate 1-
2.14  T-cell proliferation assay
T-cell proliferation was evaluated
72 hours with DC pulsed with no added protein, K
DC to PBMC or IVS ratio of 1:30. After
collected and frozen for future
with 1 µCi /well of [3H]thymidine and incubated for another 18 h
then harvested onto filter papers, tr
analyzed on a beta counter. 
 
2.15  Enzyme-linked immunospot assay
An IFN-  enzyme-linked immunospot (ELISPOT) assay to measure
secreting cells in response to antigen was performed
International). ELISPOT plates
capture antibody and incubated for 24 h
with complete media and PBMC or IVS cells were
pulsed with various HERV-K antigens plated at 5 x 10
24 hours at 37°C and then washed and incubated with the
25°C. Plates were washed and incubate
hours at 25°C. Plates were washed again and developed
indolyl-phosphate/nitro blue tetrazolium 
10 to 60 minutes at 25°C until the desired color appeared
with water, allowed to dry, and spots were counted using an ELISPO
Technologies). 
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 in patient PBMC or IVS cells by restimulation for 
-SU protein, or KLH control
 72 hours of incubation, the supernatants were 
 cytokine secretion assays.  The remaining cells were pulsed 
ours at 37°C.
ansferred to scintillation vials with scintillation fluid, and 
 
 using a commercial kit (Biosource 
 were coated with 10 µg/ml of purified anti-human IFN
ours at 4°C.  Plates were then blocked for 2 h
 plated at 1 x 105 per well with DCs 
3
 per well. Plates were incubated for
 detection antibodies for 2 h
d with streptavidin horseradish peroxidase
 by adding 5-bromo-
(BCIP/NBT) substrate solution and incubating for 
. Plates were washed thoroughly 
T reader (C.T.L. 
 protein, at a 
 Cells were 
 cytokine-
-γ 
ours 
 
ours at 
 for 2 
4-chloro-3-
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2.16  CTL assay 
 CTL assays were performed in round-bottomed 96-well plates using a standard 4-
hour 51Cr-release assay 242.  Human primary tumor or benign cells lines (target cells) were 
pulsed with HERV-K or KLH control protein for 16 hours at 37°C using the BioPORTER 
transfection reagent described previously.  Target cells were removed from flasks via EDTA 
buffer, pelleted and resuspended in 500 µl media and 75µCi of chromium.  After incubating 
for 2 hours at 37°C, cells were washed with media 3 times and radioactive waste was 
discarded properly.  5 X 104/ml target cells were then resuspended in media.  5 X 106/ml 
autologous PBMCs or IVS cells (effector cells) were also resuspended in media.  The 
effector cells and target cells were then combined in the plates and incubate for 4 hours at 
37°C.  Effector to target cell ratios were plated at 100:1, 50:1, 25:1, and 12.5.  The plates 
were pelleted and supernatants (100 µl) from each well were removed and counted in a 
gamma counter.  After effector and target cells are incubated for 4 hours, the amount of 
chromium release due to cell lysis is measured with a gamma counter.  % specific lysis was 
calculated by the following equation= ((Experimental value-minimum lysis)/(maximum 
lysis-minimum lysis)) x100.  Labeled target cells in media served as the minimum lysis 
value and labeled target cells in % Triton X100 served as the maximum value. 
 
2.17  Isolation of CD4+CD25+CD127dim/– regulatory T cells 
The CD4+CD25+CD127dim/– Regulatory T Cell Isolation Kit II (Miltenyi Biotec) was 
used to isolate T-regs.  PBMCs were pelleted and resuspended in 40 µl of buffer consisting 
of phosphate-buffered saline (PBS), pH 7.2, containing 0.5% bovine serum albumin (BSA), 
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and 2 mM EDTA per 1 x 106 cells.  10 µl of CD4+CD25+CD127dim/- T Cell Biotin-
Antibody Cocktail II was added to the cell suspension and incubated for 10 minutes at 4ºC. 
30 µl of buffer and 20 µl of Anti-Biotin Microbeads were added to the cell suspension and 
incubated for 15 minutes at 4ºC.   Cells were washed by adding 2 ml of buffer, pelleted, and 
resuspended in 500 µl of buffer.  An LD Column was placed in the magnetic field of a 
MACS Separator and 2 ml of buffer was added to rinse the column.  The cell suspension 
was applied to the column and the pre-enriched CD4+ unlabeled cells that passed through the 
column were collected.  Cells were pelleted, resuspended in 90 µl of buffer plus 10 µl of 
CD25 MicroBeads II, and incubated for 15 minutes at 4ºC.  Cells were then washed by 
adding 2 ml of buffer, pelleted, and resuspended in 500 µl of buffer.  A MS Column was 
placed in the magnetic field of a MACS Separator and 500 µl of buffer was added to rinse 
the column.  The cell suspension was applied to the column and unlabeled cells that passed 
through were collected.  The column was removed from the separator and placed into a 
sterile collection tube.  1 ml of buffer was placed on the column and magnetically labeled 
cells were flushed out by pushing a plunger into the column.   
 
2.18  Apoptosis Assay 
Annexin V staining precedes the loss of membrane integrity which characterizes the 
later stages of cell death, and therefore the vital dye 7-amino-actinomycin D (7-AAD), in 
conjunction with annexin V, was used to allow discrimination of early apoptotic cells. To 
measure the effects of 6H5 mAb on cellular apoptosis in vitro, ovarian cells DOV13, 
OVCAR3, and SKOV3 (5 x 105 cells/ml) were grown in their respective media and treated 
with 6H5 mAb or control mouse-IgG antibody at a concentration of 10 µg/ml at 37oC for 16 
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hours. Treated cells were harvested and resuspended in 200 µl 1× binding buffer (BD 
Pharmingen) at 1 × 106 cells per well.  Cells were stained with annexin V-allophycocyanin 
(APC) (BD Pharmingen) at room temperature for 15 minutes followed by one wash with 1 × 
annexin V binding buffer.  Cells were then incubated with 7-AAD-phycoerythrin-cyanide 7 
at room temperature for 10 minutes, and samples were analyzed on a BD FACSArray 
Bioanalyzer. The percentage of annexin V-positive cells for each cell line treated with 6H5 
mAb was determined using FlowJo software (Version 7.2.5).  
 
2.19  Statistical analysis 
Analyses were done using GraphPad Prism version 5. Statistical significance of 
differences between groups was determined by a Student's t test or a Chi-square test.  A P 
value <0.05 is considered to be statistically significant.  Adjusted residual analysis, Z-test, 
and Chi-squared test  were used in IHC data analysis.  
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Chapter 3:  Results 
 
3.1  Expression of HERV-K env mRNA in OC, benign and adjacent uninvolved patient 
tissue samples 
To investigate the expression of HERV-K env transcripts in patient tissue samples, 
RT-PCR analysis was performed using an HERV-K env SU primer pair, amplifying a 1,105 
bp DNA product.  HERV-K type 2, was also amplified resulting in a 1,195 bp DNA product.  
HERV3 (1,745 bp) and HERV-E41 (1,349 bp) primer pairs amplifying other HERV families 
were used as negative controls and amplification of β-actin was used as a positive control.  
Once the RT-PCR products were run an agarose gel, band intensities were based on the 
following scale:  +++ represent very intense bands, ++ represent strong bands, + represent 
average to weak bands, and – represents no bands seen.  Overall, the expression of HERV-K 
env mRNA was assessed in cancer samples (n=29) and benign samples (n=17).  Some of 
these samples originate from patients with both cancer and uninvolved or benign specimens.  
Representative gel documentation of RT-PCR products from particular patients is seen in 
Figure 6 depicting these band intensities.   In the OC samples tested, 7 (24.14%) samples 
displayed an HERV-K band with +++/++ intensity, 13 (44.83%) with + intensity, and 9 
(31.03%) with – intensity.  In comparison, in the benign or adjacent uninvolved samples 
tested, only 1 (5.88%) sample displayed an HERV-K band with +++/++ intensity, 3 
(17.65%) with + intensity, and the majority 13 (76.47%) with – intensity.  RT-PCR products 
for HERK-type 2 and HERV3 had varying results with no trend seen.  The majority of 
patients tested had HERV-E41 bands with – intensity.  As seen in the gel documentation, a 
patient diagnosed with a benign cyst produced an HERV-K band of – intensity.  Another 
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patient diagnosed with papillary serous carcinoma produced an HERV-K band of + 
intensity.  Patients #103 and #65, both diagnosed with metastatic carcinoma, produced 
HERV-K bands of ++ and + intensities respectively.  Of great importance, mRNA from 
autologous tumor and benign samples showed higher expression in the tumor sample 
compared to the benign sample.  Similarly, mRNA from autologous tumor and adjacent 
uninvolved sample showed a higher expression in the tumor sample compared to the 
adjacent uninvolved.  We conclude that gene expression of HERV-K was higher in OC 
tissue samples in comparison to benign and uninvolved samples.   
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Figure 6:  HERV env mRNA expression in OC, benign and adjacent uninvolved biopsies 
via RT-PCR.  Each set of lanes for a given amplified gene represents the RT-PCR 
expression pattern using HERV-K Type 1 (HERV-K(1)), HERV-K Type 2(HERV-K(2)), 
ERV3, HERV-E and β-actin primers.  Gel documentations of various samples are seen on 
the left.  Of great importance, among tissue pairs from the same patient, HERV-K 
expression is seen in tumor but not in benign tissue.  A table at the bottom summarizes the 
data from RT-PCR assays indicating that a significantly greater number of cancer samples 
had +++/++ and + designations when compared to benign samples.  Benign samples had a 
statistically greater number of samples with – designations when compared to cancer 
samples. Black arrows represent tissues derived from the same patient. A Pearson's chi-
squared test was used to calculate significance.   
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3.2  Expression of HERV-K env protein in primary samples from OC, benign and 
adjacent uninvolved tissues 
After detecting HERV-K genes at a higher transcriptional level in OC samples 
compared to benign and adjacent uninvolved samples, we next inquired whether HERV-K 
SU envelope protein was expressed in primary samples.  To accomplish this, we used a 
monoclonal anti-HERV-K antibody (6H5 mAb) made using a standard hybridoma 
technology, as described in the Materials and Methods section, to label the cellular 
distribution of viral components via IHC.  Representative images from various patient 
tissues are shown in Figure 7.  Positivity is shown by the brown chromagen deposits in the 
images.  IHC data from the tissues (n=406) show that HERV-K env expression is confined 
to the outer layer and to the cytoplasm in OC samples such as endometrioid adenocarcinoma 
and serous adenocarcinoma.  No staining is seen in benign cysts or adjacent normal tissues.  
This data is in agreement with the RT-PCR data.  We did not find a statistically significant 
association between envelope expression and patient age at diagnosis, race or ethnicity, 
disease stage or grade, or node-positive status.  Statistical data is presented in Table 2.     
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Figure 7:  HERV-K env protein expression in OC, benign and adjacent uninvolved biopsies 
via IHC.   Examples of immunostaining of endometrioid adenocarcinoma (A, B, C, and D), 
serous adenocarcinoma (E, F, G, and H), benign cyst (I and J), and normal epithelium 
biopsies (K and L) with 6H5: HERV-K+ cancer cells were detected in endometrioid 
adenocarcinoma (C and D) and serous adenocarcinoma (G and H).  HERV-K expression 
was not detected in benign cysts or normal epithelium biopsies.  The left column represents 
40X and right column represents 10X power. The bottom table depicts statistical data for the 
samples (n=406) screened.  
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 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 8.134
a
 3 0.043 
Likelihood Ratio 8.840 3 0.032 
N of Valid Cases 406   
 
Table 2:  The expression profile of HERV-K in ovarian tissues using anti-HERV-K monoclonal Ab 
(6H5).   Statistical data corresponding to IHC data. Adjusted residual analysis, Z-test, and Chi-
squared test  were used for statistical analysis.  
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3.3  Cell surface expression of HERV-K env protein in primary samples from OC, 
benign and adjacent uninvolved tissues 
Next, we wanted to expound on the translational data and confirm HERV-K 
expression on the cell surface.  To accomplish this, we used 6H5 mAb to label the cellular 
distribution of viral components via IFS and subsequent confocal microscopy.  We first 
detected surface and cytoplasmic expression of HERV-K env protein in the established 
human OC cell line, DOV13.  The confocal image in Figure 8 confirms that indeed HERV-
K expression is seen on the surface and in the cytoplasm of these cells.  FACS data 
presented in Figure 9 confirms this data, indicating 53% of the cell population is positive for 
surface and 86% of the cell population is positive for cytoplasmic expression of HERV-K.  
We next focused on HERV-K protein expression in our primary cell lines.  Figure 10 
presents confocal images of OC cells obtained from a patient diagnosed with serous 
carcinoma.  The images show that HERV-K env expression is confined to the cell surface.  
In contrast, Figure 11 presents images of adjacent uninvolved cells derived from a patient 
diagnosed with mullerian borderline tumor with isolated foci of invasion. HERV-K env 
expression on the cell surface is not observed in these cells.  This data also confirmed that 
activation of HERV-K indeed correlates with clinical or histological characteristics of OC 
patients.  This data is in accordance with the previous RT-PCR, IHC, and FACS data. 
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Figure 8:  Detection of surface (Non-perm) and cytoplasmic (Perm) expression of HERV-K 
env protein in the established OC cell line, DOV13, via IFS and confocal microscopy.  
DOV13 cells were EDTA-digested, pelleted on grown on glass coverslips overnight at 37°C.  
Cells were either permeabilized with FACS permeabilization buffer or fixed with FACS 
fixation buffer and then labeled with 6H5 antibody followed by an anti-mouse-IgG Alexa 
Fluor 488 conjugated antibody.   Confocal microscopy images show both surface and 
cytoplasmic expression of HERV-K.   
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Figure 9:  Detection of surface (Non-perm) and cytoplasmic (Perm) expression of HERV-K 
env protein in the established OC cell line, DOV13.  DOV13 cells were EDTA- digested, 
pelleted and either permeabilized with FACS permeabilization buffer or fixed with FACS 
fixation buffer and then labeled with 6H5 antibody followed by an anti-mouse-IgG Alexa 
Fluor 647 conjugated antibody.  FACS analysis on 6H5 conjugated to Alexa Fluor 647 
labeled DOV13 cells reveals both surface (blue line) and cytoplasmic (red line) HERV-K 
expression.   
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Figure 10:  Detection of surface expression of HERV-K env protein in primary OC cells by 
IFS and subsequent fluorescent microscopy.  Pt#222 was diagnosed with serous carcinoma.  
After tissue harvest, cells were plated and allowed to expand.  Cells were EDTA-digested, 
pelleted, and grown on glass coverslips.  Cells were then fixed and labeled with 6H5 
antibody, followed by anti-mouse-IgG Alexa Fluor 488 conjugated antibody.  Fluorescent 
images depict surface expression of HERV-K in these OC patient primary cells.  Cells 
labeled with only the secondary anti-mouse-IgG Alexa Fluor 488 conjugated antibody were 
used as a negative control. 
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Figure 11:  Detection of surface expression of HERV-K env protein in primary OC cells by 
IFS and subsequent fluorescent microscopy. Tumor and adjacent uninvolved tissue were 
harvested from #105, diagnosed with mullerian borderline tumor with isolated foci of 
invasion.  Cells were EDTA-digested, pelleted, and grown on glass coverslips.  Cells were 
then fixed and labeled with 6H5 antibody, followed by anti-mouse-IgG Alexa Fluor 488 
conjugated antibody.  Images of tumor cells depicts cell surface staining for HERV-K.   
Images of adjacent uninvolved cells depict no surface expression of HERV-K in these cells.  
Cells labeled with only the secondary anti-mouse-IgG Alexa Fluor 488 conjugated antibody 
were used as a negative control. 
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3.3  Primary patient cell characterization 
 Recent studies have shown that non-neoplastic cells, notably the stromal cells of 
human carcinomas, are active and essential collaborators with neoplastic epithelial cells 
within tumor masses.    The diverse stromal cell types within tumors are all members of 
several mesenchymal cell lineages that generate both connective tissue and immune cells 
and are biologically very different from epithelial cells whose transformation drives the 
growth of carcinomas243.  For decades, intermediate filament proteins have been used as 
molecular markers in diagnostic histopathology 244-246, and evidence suggests that aberrant 
expression of individual cytokeratins or vimentin results in abnormal cell behavior 247. 
Indeed it has been determined that epithelial and mesenchymal cells undergo dramatic 
changes in their cytoskeletal scaffolds during tumorigenesis.  
Vimentin is the main intermediate filament (IF) protein in mesenchymal cells 248, and 
maintains cytoarchitecture and tissue integrity 249, 250.  However, a growing body of evidence 
has focused on the role of vimentin in cell migration and epithelial-mesenchymal transition 
of epithelial carcinomas 248.  Studies of human epithelial carcinoma cell lines have 
demonstrated that vimentin expression is induced in invasive cells lines 251-253 and in BC, its 
expression is correlated with poor prognosis 254.  Also, studies have proven that occurrence 
of metastasis in hepatocellular carcinoma is significantly associated with over-expression of 
vimentin 255.  In a recent study, Wang Y, Wu R, Cho KR, Thomas DG, Gossner G, Liu JR, 
Giordano TJ, Shedden KA, Misek DE, and Lubman DM compared protein expression in 
low stage (Stage 1) versus high stage (Stages 3/4) ovarian serous adenocarcinomas and 
determined that vimentin was significantly overexpressed in the high stage tumors as 
compared with the low stage 256.  It is unknown whether vimentin expression is a marker for 
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epithelial-mesenchymal transition (EMT)-like changes or if vimentin expression is required 
for the invasive behavior of cells 248. 
Cytokeratins are keratin-containing intermediate filaments found in the 
intracytoplasmic cytoskeleton of epithelial tissue.  Cytokeratins are composed of a family of 
at least 20 different polypeptides and are distributed in both normal and neoplastic tissues 
244
.  Epithelial ovarian tumors are thought to arise from the ovarian surface epithelium and 
contain cytokeratins 7, 8, 18, and 19 257.  However, loss of cytokeratin expression has been 
found to occur in the primary tumors and is associated with factors predictive for an 
unfavorable prognosis for patients with BC.   In one study, IHC analysis of BC tissues 
showed that reduced cytokeratin 18 expression was correlated with poor clinical outcome 
258
.  Also, down-regulation of cytokeratin 19 expression and overexpression of vimentin 
were found in highly aggressive BC cell lines exhibiting strong migratory and invasive 
abilities 259.   Loss of cytokeratin 8 and 18 expression and concurrent up-regulation of 
vimentin has also been found to suggest that disseminated tumor cells have acquired a 
mesenchymal-like, aggressive phenotype 247.  Alternatively, numerous others studies have 
shown that coexpression of vimentin and cytokeratin correlates with invasiveness and 
metastasis 260-263. 
Thus, our next goal was to characterize the primary cells harvested and used in our 
experiments to determine populations of epithelial and mesenchymal cells and changes in 
cytoskeletal scaffolds.  We therefore employed the following antibodies: anti-vimentin to 
identify cells of mesenchymal origin, anti-pan cytokeratin to identify epithelial cells, and 
anti-NCL-L-5D3 (cytokeratin 8 and 18) to identify tumor epithelial cells.  After labeling the 
primary cells, we analyzed them via FACS and confirmed these results visually via confocal 
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microscopy.  Table 3 lists the percentage of cells positive for the respective antibody used in 
both tumor and benign samples.  As seen in Figure 12, there is positive staining for both  
cytokeratin for both OC and benign samples indicating the presence of epithelial cells.  
Positive staining is also seen for vimentin for both OC and benign samples indicating 
mesenchymal cells or cells undergoing epithelial-to mesenchymal transition.  Both benign 
and OC samples stained positively for NCL-L-5D3 indicating the presence of tumor 
epithelial cells.  This positive co-expression of cytokeratin and vimentin corresponds to 
results from other studies discussed previously.  Patient #65 diagnosed with metastatic 
adenocarcinoma displayed very high coexpression of cytokeratins and vimentins which 
correlated with the cell’s strong migratory and invasive behavior.   
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Table 3:  Primary cell line characterization: Epithelial, mesenchymal, and tumor epithelial 
cell populations via FACS.  After harvesting patient tissues and culturing cells, samples 
were characterized via FACS. Cells were stained with anti-vimentin, anti-pan cytokeratin, 
and anti- NCL-L-5D3 antibodies and subjected to flow cytometry analysis.  Percentages 
indicate populations of cells positive for the respective antibody used.   
 
 
 
68 
 
Figure 12:  Primary cell line characterization:  Epithelial and mesenchymal cell populations 
via IFS and confocal microscopy. Benign cells from #144 diagnosed with benign disease 
and tumor cells from #222 diagnosed with serous carcinoma are shown.  Human primary 
cells were characterized approximately 4 days post-harvest to determine specific cell 
populations.  Cells were grown on glass coverslips, fixed, and labeled with anti-cytokeratin 
and anti-vimentin followed by a secondary anti-mouse IgG Alexa Fluor 488 conjugated 
antibody.  Secondary antibody only was used as a negative control and indeed no staining is 
seen.  The figure shows positive staining for cytokeratin for both OC and benign samples 
indicating the presence of epithelial cells.  Positive staining is also seen for vimentin for 
both OC and benign samples indicating mesenchymal cells or cells undergoing epithelial-to 
mesenchymal transition. 
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3.4  Individual cases of patient characterization 
We next focused our attention on an OC patient diagnosed with metastatic 
adenocarcinoma.  Figure 13 depicts cultured ascites cells from this patient one day post-
harvest in 2-D culture to display cell morphology.  These cells are morphologically similar 
to epithelial cells and not stromal cells which are classified by a cell body and cell processes 
that are long and thin.  After harvesting the ascites on day 0, we cultured cells on 0.8% 
agarose plates in serum-free Mammocult media in order to support stem cell populations.  
These cells were then termed “tumorspheres” as their appearance was of suspended spheres.  
RT-PCR data for this patient at both time points, asserts expression of mRNA HERV-K type 
1 and type 2 transcripts, and ERV-3 transcripts.   However, expression is clearly increased 
after tumorsphere culture.  Expression of HERV-E41 transcripts are seen after tumorsphere 
culture.  Figure 14 displays a QIFIKIT assay employed in order to quantify the number of 
HERV-K surface molecules on ascites cells one day post-harvest.   164,528  HERV-K 
molecules were determined to be expressed on the cell surface.  Finally, Figure 15 reveals 
FACS analysis of tumorspheres confirming HERV-K, epithelial, mesenchymal and 
epithelial cancer cell positivity after staining with 6H5 mAb, anti-vimentin, anti-cytokeratin, 
and anti-NCL-L-5D3 antibodies at 1 day and 7 days post-harvest.  After tumorsphere 
culture, populations of cytokeratin, vimentin, tumor epithelial, HERV-K positive 
populations increased.   We are also very interested in determining OC stem cell 
populations.  Therefore, we stained cells with anti-CD133 and anti-CD44 cancer stem cell 
markers.  FACS analysis shows that populations of cells positive for CD44 increased, but  
CD133 positive populations decreased slightly. 
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Figure 16 illustrates another patient of interest, diagnosed with metastatic serous 
carcinoma.  After harvesting the ascites cells, we cultured them in tumorsphere forming 
conditions as seen in the figure.  RT-PCR data for this patient at both time points, asserts 
expression of mRNA HERV-K type 1 and type 2 transcripts, ERV-3, and HERV-E41 
transcripts .   However, expression is clearly increased in all transcripts after tumorsphere 
culture, except for ERV3 which decreased slightly.  Finally, we wanted to determine if 
HERV-K expression and other characteristics changed in response to this cancer stem cell 
supporting environment.  After staining with 6H5 mAb, anti-vimentin, anti-cytokeratin, anti-
NCL-L-5D3, anti-CD133, and anti-CD44, the results in Figure 17 show that the percentage 
of positive populations for each marker increased after tumorsphere culture, except for 
CD133 which decreased slightly.   
 
 
 
 
 
 
 
 
71 
 
 
Figure 13:  Human primary cell line characterization:  HERV-K mRNA expression and cell 
morphology in Patient #65 ascites and tumorspheres.  Patient #65 was diagnosed with 
metastatic adenocarcinoma.  RT-PCR data for cells in culture 1 day post-harvest and 7 days 
post-harvest in tumorsphere conditions.   2D images of cells in culture 1 day post-harvest 
and 7 days post-harvest in tumorsphere conditions.  
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Figure 14:  Human primary cell line characterization:  Quantitation of HERV-K cell surface 
molecules in Patient #65 ascites. Patient #65 was diagnosed with metastatic 
adenocarcinoma.  Quantitation of HERV-K env molecules on the surface of primary cells 
via QIFIKIT and FACS analysis.  The gray, filled line represents the isotype control, the red 
line represents the HERV-K positive population and the blue line represents a series of 6 
bead populations coated with well-defined quantities of a mouse monoclonal antibody.  
164,258 surface molecules of HERV-K were present on the surface of these cells. 
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Figure 15:  Human primary cell line characterization:  Epithelial, mesenchymal, HERV-K+, 
and stem cell populations in patient #65 ascites and tumorspheres via FACS.   Patient #65 
was diagnosed with metastatic adenocarcinoma.  After patient tissue was harvested, cells 
were gown in serum-free Epicult medium on 0.8% agarose coated plates to support 
tumorsphere formation.  Primary cells were characterized via staining 1 day post-harvest and 
7 days post-harvest with 6H5 mAb (HERV-K expression), anti-vimentin Ab (mesenchyme-
derived cells), anti-cytokeratin mAb (epithelial cells), anti-NCL-L-5D3 mAb (tumor 
epithelial cells), anti-CD44 mAb (OC stem cells), and anti-CD133 mAb (OC stem cells), 
followed by FACS analysis.  A table at the bottom summarizes the FACS data.   
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Figure 16:  Human primary cell line characterization:  HERV-K mRNA expression and cell 
morphology in Patient #222 ascites and tumorspheres.  Patient #222 was diagnosed with 
serous carcinoma.  RT-PCR data for cells in culture 1 day post-harvest and 7 days post-
harvest in tumorsphere conditions is shown.   2D images of the cells in culture 1 day post-
harvest and 7 days post-harvest in tumorsphere conditions is shown. 
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Figure 17:  Human primary cell line characterization:  Epithelial, mesenchymal, HERV-K+, 
and stem cell populations in Patient #222 ascites and tumorspheres via FACS.  Patient #222 
was diagnosed with serous carcinoma.  Primary cells were characterized 1 day post-harvest 
and 7 days post-harvest to determine differences.  Primary cells were characterized via 
staining with anti-vimentin Ab (mesenchyme-derived cells), anti-cytokeratin Ab (epithelial 
cells), anti-NCL-L-5D3 Ab (tumor epithelial cells), anti-CD44 Ab (OC stem cells), anti-
HERV-K env protein (6H5) and anti-CD133 Ab (OC stem cells), and subsequent FACS 
analysis depicted in the bottom panel. A table at the bottom summarizes the FACS data.   
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3.5  Levels of anti-HERV-K Abs in OC, benign patient, and normal donor serum 
samples 
Our next objective was to determine if amounts of anti-HERV-K antibodies are 
different between OC, benign patient, and normal donor serum samples.  We obtained 
several patients with various serum draws post operation.  Therefore, “0m” indicated a 
serum draw one day before the surgery and “6m” indicated a serum draw 6 months post-
surgery.   Human patient serum samples were diluted and added to ELISA plates coated 
with purified HERV-K env protein.  First we assayed 2 OC patients, #14 and #22, with two 
blood draw dates and 4 patients with benign disease, #19, #16, #32, #34, and several 
dilutions.   As seen in Figure 18, titers of anti-HERV-K antibodies were significantly higher 
in OC patients compared to patients with benign disease.  Also in this graph, serum taken 
the day before surgery (0m) was compared to serum taken 6 and 12 months post-surgery. No 
trends were seen in antibody levels and further testing needs to be completed with longer 
draw date span samples and in patients who experience tumor recurrence.  A summary graph 
in Figure 19 shows that anti-HERV-K antibody titers are significantly higher in patients with 
OC (n=25) compared to patients with benign disease and normal donors (n=21).  This data 
confirms that anti-HERV-K antibodies present in patients at different stages of disease and 
correlate with clinical and histological characteristics.  
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Figure 18:  ELISA assay with sera from OC and patients with benign disease.  ELISA assay 
was used to detect various titers of anti-HERV-K antibodies in OC patient and patients with 
benign disease.  Patient diagnoses are as follows:  #14 = serous borderline, #22 = high grade 
serous carcinoma, #19 = teratoma, #16 = teratoma, #32 = teratoma, #34 = teratoma.  Human 
sera was diluted and added to blocked ELISA plates coated with purified HERV-K protein.  
0m indicates a serum draw days before the surgery to remove the tumor or benign disease 
and 6m indicates a serum draw 6 months post-surgery.  Significantly more anti-HERV-K 
antibodies were found in OC patient sera compared to patients with benign disease. 
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Figure 19:  ELISA Summary: Detection of anti-HERV-K antibodies in serum from OC 
patients, patients with benign disease, and normal donors.  ELISA assay was used to detect 
anti-HERV-K antibodies in OC patients, patients with benign disease, and normal donors.  
Human sera was diluted and added to blocked ELISA plates coated with purified HERV-K 
protein.  Significantly more anti-HERV-K antibodies were found in OC patient sera (n=25) 
compared to patients with benign disease and normal controls (n=21).  A student’s t-test was 
used to calculate significance.   
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3.6  Characterization of lymphocytes obtained from OC and benign samples 
 Our encouraging results from the first aim served as a great precedent for our second 
aim, to evaluate the immune responses triggered by HERV-K antigen in OC and benign 
patients.  Our first objective was to characterize the different types of lymphocytes present 
in the PBMC and IVS samples.  This is important because T cell infiltrates are frequently 
associated with a favorable prognosis for many epithelial cancers 216, 264-272.  Specifically, a 
plethora of studies have documented infiltration by both CD4+ and CD8+ T cells in epithelial 
OC.  CD4+ helper T cells have no cytotoxic or phagocytic activity but instead activate other 
immune cells.  Examples of these activities include aiding in B cell antibody class 
switching, activation and growth of cytotoxic CD8+ T cells, and bactericidal activity of 
phagocytes.  There are exceptions, including T-regs, natural killer cells and cytotoxic T cells 
that express CD4, but these are not considered T helper cells.  CD8+ cytotoxic T cells induce 
death in tumor cells or cells that are infected with viruses or other pathogens.  Studies have 
shown that patients with ovarian tumors containing dense infiltrates of CD3+CD8+ T cells 
experience unexpectedly favorable progression-free and overall survival 113, however the 
association of tumor infiltrating lymphocytes subpopulations with clinical outcome remains 
controversial 273 .   
NK cells are widely known for their ability to kill cells infected by certain viruses, 
intracellular bacteria and tumor cells.  Also, their cytolytic activity and secretion of 
cytokines and chemokines are crucial components of the innate immune system 274, 275.  In a 
recent study, autologous NK cells had the ability to recognize and kill human ovarian 
carcinoma cells 276.  Similarly, Alves PC, Andrade LA, Petta CA, Lorand-Metze I, Derchain 
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SF, and Guimarães F demonstrated that effector cells enriched with CD56+ lymphocytes 
were the main variable affecting target cell killing in patients with ovarian neoplasia 277.  
 As described in the Introduction, T-regs are a subpopulation of T lymphocytes that 
down-regulate the immune response and accumulation of intratumoral T-regs was found to 
be associated with a high mortality rate in OC patients146.  Conversely, another group 
determined that the presence of T-regs and activated CD4+ cells within the tumor 
microenvironment was associated with improved overall progression-free survival in 
patients with OC 273. In conclusion, it is the intricate balance between these effector cells 
and regulatory T cells that is critical in determining patient outcome. 
To classify the different populations, we stained cells with the following antibodies 
and analyzed them by FACS:  anti-CD4 to identify T helper cells, anti-CD8 to identify 
CTLs, anti-CD25 to identify activated T and B cells, anti-CD56 to identify NK cells and 
anti-FoxP3 to identify T-regs.  Table 4 shows that upon transition from PBMC to IVS cell, 
the percentage of T helper cells, CTLs, activated T and B cells, NK cells, and T-regs 
increased in a patient diagnosed with benign disease, #182.  A second patient diagnosed with 
a benign cyst, #151, displayed an increase in the percentage of T helper cells, CTLs, 
activated T and B cells, NK cells, but a slight decrease in T-regs. The remaining 2 OC 
patients all displayed an increase in the percentage of T helper cells, CTLs, and activated T 
and B cells, however a decrease in NK and T-reg positive cells.  
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Table 4:  Characterization of patient PBMCs and IVS cells:  CD8+, CD4+, CD25+, CD56+, 
and FoxP3+ populations via FACS.  Cells were stained with anti-CD4 (T helper cells), anti-
CD8 (cytotoxic T cells), anti-CD25 (activated T and B cells), anti-CD56 (natural killer 
cells), and anti-FoxP3(T-regs) antibodies and then analyzed on a BD FACS array.  After 
transition from PBMCs to IVS cells, populations of all specific cell types in both OC and 
patients with benign disease either increased (green ↑) or decreased (red ↓).   
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3.8  Changes in T cell proliferation in OC patients compared to samples from patients 
with benign disease and normal donors 
Our next goal was to focus on T-cell responses in ovarian patients.  Many agents can 
specifically or nonspecifically induce T cell activation resulting in proliferation of activated 
T cells.  In this work, we were interested in determining if HERV-K env protein could 
specifically induce T cell proliferation.  To accomplish this, we isolated PBMCs from patient 
blood samples and generated IVS cells by combining PBMCs with autologous DCs pulsed 
with HERV-K for 7 days.  T cell proliferation specifically induced by DCs pulsed with 
HERV-K env protein or KLH control protein were then compared between autologous 
PBMC and IVS cells and between OC, patients with benign disease or normal donors via 
[3H] thymidine incorporation assay.  Figure 20 depicts 2 patients with benign disease and 1 
with OC.  T cell proliferation was clearly higher in the OC patient compared to the patients 
with benign disease.  Also, DCs pulsed with HERV-K induced greater T-cell proliferation 
compared to DC pulsed with KLH, unpulsed DCs, or media alone.  Another T cell 
proliferation assay is depicted in Figure 21 showing results for 4 patients with OC, one with 
benign disease and 3 normal donors.   T cell proliferation was higher in OC patients 
compared to the patient with benign disease and the normal donors.  DCs pulsed with 
HERV-K induced greater T cell proliferation compared to DCs pulsed with KLH, unpulsed 
DCs, or media alone.  Finally, DCs pulsed with HERV-K induced greater T-cell proliferation 
in IVS cells than in PBMCs. 
Figure 22 illustrates a T cell proliferation summary including OC patients (n=8) and 
patients with benign disease or normal donors (n=6). Overall, HERV-K antigen induced 
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significantly greater T cell proliferation in IVS cells in OC patients compared to the control 
protein.   HERV-K antigen also induced significantly greater T cell proliferation of IVS cells 
in OC patients than in benign disease patients and normal controls.    
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Figure 20:  T cell proliferation assay.  IVS cells were combined with DCs pulsed with 
HERV-K protein or with KLH control protein.  Cells were also combined with media alone 
and unpulsed DCs as negative controls.  T cell proliferation is clearly greater in patients with 
OC compared to benign diseases when IVS cells are combined with HERV-K pulsed DCs.   
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Figure 21:  T cell proliferation assay.  Patient diagnoses are as follows:  #8=benign simple 
cyst, #7=metastatic adenocarcinoma, #14=serous borderline, #15=serous borderline, ND1-
3=normal female donors.  PBMCs or IVS cells were combined with DCs pulsed with cRNA 
for the HERV-K protein or cRNA for E6 control protein.  T cell proliferation is clearly 
greater in patients with OC compared to benign diseases when IVS cells are combined with 
HERV-K cRNA pulsed DCs.   
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Figure 22:  T cell proliferation summary.  IVS cells were combined with DCs pulsed with 
HERV-K protein or with KLH control protein.  T cell proliferation is significantly greater in 
patients with OC (n=8) compared to benign diseases or normal donors (n=6) when IVS cells 
are combined with HERV-K pulsed DCs.  T cell proliferation is significantly greater when 
OC patient IVS cells are combined with HERV-K pulsed DCs as compared to KLH pulsed 
DCs. ).  A student’s t-test was used to calculate significance.  b=benign or normal, t=tumor. 
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3.9  Changes in IFN-γ secretion in OC patients compared to samples from patients with 
benign disease and normal donors 
IFN-γ is secreted by activated CD4+ and CD8+ cells and is critical for innate and 
adaptive immunity and for tumor control.  Therefore, we utilized an ELISPOT assay to 
analyze IFN–γ production at the single cell level.   In this particular assay, a spot forms at 
the site where secreted cytokine is bound; therefore, one spot is equal to one molecule 
secreting cell.  The microplate is then subjected to an automated ELISPOT reader to 
determine the amount of spots per well.  This allows the frequency of cells secreting IFN–γ 
to be calculated.  To begin this assay, we isolated PBMCs from patient blood samples and 
generated IVS cells by combining PBMCs with autologous DCs pulsed with HERV-K for 7 
days.  1x105 KSU IVS cells or PBMCs were combined with media, 5x103 autologous DCs, 
5x103 DCs pulsed with HERV-K protein or 5x103 DC pulsed with KLH protein, and 
incubated for 16 hours before adding the color substrate.   IFN–γ production, specific to 
HERV-K env protein pulsed DCs, used as antigen presenting cells, was then compared 
between PBMC and IVS cells obtained from the same donors.  IFN–γ production was also 
compared between OC patients, patients with benign disease, and normal donors. 
Figure 23 illustrates an IFN–γ ELISPOT assay with 1 OC patient, diagnosed with 
adenocarcinoma, and 3 normal donors.  The image at the top is the actual ELISPOT plate, 
and the column graph below quantifies the number of spots for this plate.  Clearly more 
IFN-γ secretion is observed when IVS cells from the OC patient are combined with HERV-
K pulsed DCs, compared to all 3 normal donors.  Also, there is clearly less IFN-γ secretion 
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when IVS or PBMCs are combined with media alone, unpulsed DCs, or DCs pulsed with 
KLH protein, as compared to HERV-K pulsed DCs.   
There has been great interest in the expression of retroviral transmembrane proteins 
in human diseases.  As discussed previously in the Introduction, the env genes encode a 
surface (SU) protein and a transmembrane (TM) protein.  The function of the TM protein is 
to hold the SU domain in the viral envelope and it aids in membrane fusion.  
Transmembrane envelope proteins of different retroviruses have been correlated with 
immunosuppressive properties 278, 279.   After demonstrating the strong expression of HERV-
K in melanomas 76, it was established that there was cell surface expression of the TM 
envelope protein in melanomas and melanoma cell lines, and this protein may interact with 
the neighboring lymphocytes and induce immunosuppression.  Alternatively, in our lab, we 
discerned a positive correlation between anti-HERV-K TM serum reactivity and tumor 
progression in human BC samples.   We also discovered that the HERV-K TM envelope 
protein is capable of triggering strong humoral immune responses.  Figure 24 illustrates 
another IFN-γ ELISPOT assay including 1 normal donor and 1 OC patient whose 
lymphocytes were obtained 1 days before surgery (0 month) and again sampled 6 months 
after the tumor was removed.   We additionally combined IVS or PBMCs with DCs pulsed 
with the TM protein.  IFN-γ production is clearly seen when the OC patient IVS sample is 
combined with HERV-K TM and HERV-K pulsed DC cells.  There was no IFN-γ production 
seen with PBMC cells or in the normal donor.  This data further substantiates our previous 
data that TM is not immunosuppressive.     
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Figure 25 display a summary of IFN-γ ELISPOT assays including OC patients (n=9) 
and patients with benign disease or normal donors (n=6).  We concluded that significantly 
more IVS cells from OC patients secrete IFN-γ than PBMCs from OC patients when 
stimulated with DCs pulsed with KSU protein.  Also, significantly more IVS cells from OC 
patients secrete IFN-γ when combined with KSU than with control protein.  Finally, 
significantly more IVS cells from OC patients secrete IFN-γ than IVS cells from benign 
disease patients and normal donors.   
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Figure 23:   IFN-γ ELISPOT assay.  Patient #103 was diagnosed with adenocarcinoma.  
ND59, ND10, and ND11 represent normal female donors.  An image of an ELISPOT plate is 
displayed at the top.  KSU IVS or PBMC were combined with DCs pulsed with HERV-K 
protein, DCs pulsed with KLH control protein, media alone, or unpulsed DCs.  A purple spot 
represents one molecule secreting cell.  Spots are clearly seen when IVS cells are combined 
with HERV-K pulsed DCs but not media, unpulsed DCs, or DCs pulsed with control protein 
in the OC patient.  Considerably less or no spots are seen in the normal donors.  A column 
graph representing the number of spots in each patient from the same ELISPOT plate is 
displayed at the bottom.   
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Figure 24: IFN-γ ELISPOT:  Patient #153 was diagnosed with high grade papillary serous 
carcinoma and BC.  ND11 represents a normal female donor.  KSU IVS or PBMC were 
combined with DCs pulsed with HERVK protein, DCs pulsed with KLH control protein, 
DCs pulsed with TM protein media alone, or unpulsed DCs.  A purple spot represents one 
molecule secreting cell.  Spots are clearly seen when IVS cells are combined with HERV-K 
pulsed DCs but not media, unpulsed DCs, or DCs pulsed with control protein in the OC 
patient.  Considerably less or no spots are seen in the normal donors. 0 and 6 months 
indicate lab blood draw dates post operation. 
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Figure 25:  Summary for ELISPOT.  OC patients (n=9) are compared with patients with 
benign disease or normal donors (n=6).  KSU IVS or PBMC were combined with 5x103 DCs 
pulsed with HERV-K protein, DCs pulsed with KLH control protein, unpulsed DCs, or 
media alone.  Significantly more spots are seen when IVS cells are combined with HERV-K 
pulsed DCs compared to IVS cells combined with KLH pulsed IVS cells in OC patients.  
Significantly more spots are seen when IVS cells are combined with HERV-K pulsed DCs in 
OC patients compared to patients with benign disease.  Significantly more spots are seen 
when IVS cells are combined with HERV-K pulsed DCs in OC patients compared to 
PBMCs in OC patients.   A student’s t-test was used to calculate significance.   
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3.10  CTL activity using autologous OC and benign patient primary target cells 
Our paramount objective was to determine the ability of antigen specific T cells to 
kill autologous target cells expressing HERV-K.  We wanted to ensure that these antigen-
specific T cells kill only cancer cells which express HERV-K but not benign or normal cells 
that do not express HERV-K.  We also wanted to ensure that T cells could kill target cells 
from the same patient instead of an established cancer line not specific to the patient.   The 
standard CTL assay indicates the presence and cytotoxic activity of T cells to a specific 
antigen.  Target cells, primary tumor or benign cells or adjacent uninvolved cells isolated 
from patient tissue, are labeled with 51Chromium and combined with IVS cells isolated from 
autologous patient blood samples.  
Figure 26 presents a CTL assay including both tumor and adjacent uninvolved cells 
obtained from an OC patient diagnosed with malignant mixed mullerian tumor.  The results 
show that IVS cells from the OC patient exhibited higher specific lysis of tumor target cells 
compared to adjacent uninvolved cells. Also, specific lysis was higher when target cells 
were pulsed with HERV-K compared to E6 or unpulsed.  Figure 27 presents a CTL assay 
including both tumor and adjacent uninvolved cells obtained from an OC patient diagnosed 
with mullerian borderline tumor with isolated foci of invasion.  The results show that IVS 
cells from the OC patient exhibited higher specific lysis of tumor target cells compared to 
adjacent uninvolved cells. Also, specific lysis was higher when target cells were pulsed with 
HERV-K compared to unpulsed.  Specific lysis was also high when target cells were pulsed 
with E6 protein.  This possibly indicates that this female is HPV positive.  
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Figure 26:  CTL assay using human patient autologous cells as target cells:  Patient #115 
was diagnosed with malignant mixed mullerian tumor and both tumor and adjacent 
uninvolved tissue was harvested.  CTL assays were performed using a standard 4-hour 51Cr-
release assay.  Autologous primary OC tumor and adjacent uninvolved cells lines were 
pulsed with HERV-K or KLH control protein and used as target cells.  Cells were plated at 
effector to target cell ratios of 100:1, 50:1, 25:1, and 12.5:1.  Specific lysis is highest when 
autologous target cells expressing HERV-K compared to E6 protein are combined with IVS 
cells from this patient.  % specific lysis is considerably higher when IVS cells are combined 
with autologous tumors cells compared to adjacent uninvolved cells. 
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Figure 27:  CTL Assay. #105 was diagnosed with mullerian borderline tumor with isolated 
foci of invasion.  CTL assays were performed using a standard 4-hour 51Cr-release assay.  
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERV-
K or E6 control protein and used as target cells.  Cells were plated at effector to target cell 
ratios of 100:1, 50:1, 25:1, and 12.5:1.  Specific lysis is highest when autologous target cells 
expressing HERV-K compared to E6 protein are combined with IVS cells from this patient.  
% specific lysis is considerably higher when IVS cells are combined with autologous tumors 
cells compared to adjacent uninvolved cells.  
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3.11  Effects of T-reg depletion on CTL activity using autologous OC, adjacent 
uninvolved, and benign patient primary target cells 
T-regs within the tumor microenvironment are a crucial component of the tumor 
immunosuppressive network.  Therefore, our final objective was to deplete T-regs from our 
lymphocyte population and determine the effect on specific lysis of HERV-K expressing 
target cells.   We utilized a CD4+CD25+CD127dim/– regulatory T cell isolation kit in order to 
magnetically isolate T-regs from our populations.  Our lymphocytes fell into three groups:  
“T-reg-” indicated a lymphocyte population depleted of T-regs, “T-reg+” indicated a 
lymphocyte population consisting of isolated T-regs, and “both” indicated a lymphocyte 
population not subjected to the isolation kit.  CTL assays were then conducted as described 
in the Material and Methods section.  
Figure 28 includes CTL data from 2 OC patients diagnosed with adenocarcinoma 
and 2 patients diagnosed with benign disease.  IVS cells from each patient were 
magnetically separated into T-reg populations as described above, and used as effector cells.   
The results show that overall specific lysis was higher in the OC patients compared to 
patients with benign disease.  Specifically, T-reg depletion resulted in increased specific 
lysis of OC target tumor cells pulsed with HERV-K in #103.  Figure 29 displays data from 
one OC patient.  Overall, specific lysis was higher in the OC target cells compared to 
adjacent uninvolved cells.  Also, OC target cells pulsed with HERV-K showed higher 
specific lysis than the unpulsed target cells.  T-reg depletion did not exhibit a cytolytic 
advantage in this patient.   
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Figure 30 displays CTL data from 2 OC patients and 2 patients with benign disease.  
The results show that overall specific lysis was higher in the OC patients compared to 
patients with benign disease.  Also, both OC patients benefited from T-reg depletion, 
manifesting in greater specific lysis of target cells expressing HERV-K.  Figures 31 and 32 
both include CTL data from 1 OC patient and 1 patient with benign disease.  Specific lysis is 
clearly greater when target cells from the OC patient are pulsed with HERV-K compared to 
the patient with benign disease.  T-reg depletion benefited the OC patients but not the 
patients with benign disease.  Figure 33 includes CTL data from 1 OC patient and 1 patient 
with  a teratoma.  Specific lysis is clearly greater when target cells from the OC patient are 
pulsed with HERV-K compared to the patient with a teratoma.  T-reg depletion did not 
benefit these patients.  Finally, Figures 34 and 35 both include CTL data from 1 OC patient.  
Specific lysis was greater in both patients when target cells where pulsed with HERV-K 
compared to KLH control protein.  T-reg depletion benefited 1 OC patient of the two. 
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Figure 28:  CTL Assay:  Human patient autologous cells as target cells.  Primary human 
tissue was harvested from patients with various diagnoses.  CTL assays were performed 
using a standard 4-hour 51Cr-release assay.  Autologous primary OC tumor and benign cells 
were pulsed with HERV-K and used as target cells.  Effector cells were separated into T-
reg-, Treg+ and unseparated groups.  Cells were plated at effector to target cell ratios of 
100:1, 50:1, 25:1, and 12.5:1.  Specific lysis is highest when autologous cells expressing 
HERV-K are combined with IVS cells from OC patients compared to patients with benign 
disease.   
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Figure 29:  CTL Assy.  #112 was diagnosed with serous borderline carcinoma/mucinous 
borderline adenocarcinoma.  CTL assays were performed using a standard 4-hour 51Cr-
release assay.  Autologous primary OC tumor and adjacent uninvolved cells lines were 
pulsed with HERV-K and used as target cells.  Cells were plated at effector to target cell 
ratios of 100:1, 50:1, 25:1, and 12.5:1.  Specific lysis is highest when autologous target cells 
expressing HERV-K are combined with IVS cells from this patient.   
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Figure 30:  CTL assay.  CTL assays were performed using a standard 4-hour 51Cr-release 
assay.  Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with 
HERV-K and used as target cells.  Cells were plated at effector to target cell ratios of 100:1, 
50:1, 25:1, and 12.5:1.  Specific lysis is highest when autologous cells expressing HERV-K 
are combined with IVS cells from OC patients compared to patients with benign disease.   
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Figure 31:  CTL Assay.  CTL assays were performed using a standard 4-hour 51Cr-release 
assay.  Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with 
HERV-K and used as target cells.  Cells were plated at effector to target cell ratios of 100:1, 
50:1, 25:1, and 12.5:1.  Specific lysis is highest when autologous cells expressing HERV-K 
are combined with IVS cells from OC patients compared to patients with benign disease.   
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Figure 32:  CTL assays were performed using a standard 4-hour 51Cr-release assay.  
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERV-
K and used as target cells.  Cells were plated at effector to target cell ratios of 100:1, 50:1, 
25:1, and 12.5:1.  Specific lysis is highest when autologous cells expressing HERV-K are 
combined with IVS cells from OC patients compared to patients with benign disease.   
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Figure 33:  CTL assays were performed using a standard 4-hour 51Cr-release assay.  
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERV-
K and used as target cells.  Cells were plated at effector to target cell ratios of 100:1, 50:1, 
25:1, and 12.5:1.  Specific lysis is highest when autologous cells expressing HERV-K are 
combined with IVS cells from OC patients compared to patients with benign disease.   
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Figure 34:  CTL assays were performed using a standard 4-hour 51Cr-release assay.  
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERV-
K and used as target cells.  Cells were plated at effector to target cell ratios of 100:1, 50:1, 
25:1, and 12.5:1.  Specific lysis is highest when autologous target cells expressing HERV-K 
compared to KLH protein are combined with IVS cells from this patient.   
 
 
105 
%
Sp
ec
ifi
c 
Ly
si
s
T r
eg
-
bo
th
T r
eg
 
+
T r
eg
-
bo
th
T r
eg
 
+
0
10
20
30
40
100 to 1
50 to 1
25 to 1
12.5 to 1
target cells+KLH target cells +KSU
#213 high grade
serous
 
Figure 35:  CTL assays were performed using a standard 4-hour 51Cr-release assay.  
Autologous primary OC tumor and adjacent uninvolved cells lines were pulsed with HERV-
K and used as target cells.  Cells were plated at effector to target cell ratios of 100:1, 50:1, 
25:1, and 12.5:1.  Specific lysis is highest when autologous target cells expressing HERV-K 
compared to KLH protein, are combined with IVS cells from this patient.   
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Figure 36 displays a CTL assay summary including OC samples (n=28), adjacent 
uninvolved samples (n=10), and benign samples (n=18).  Overall, cytolytic activity was 
significantly greater when IVS effector cells were combined with autologous tumor target 
cells than with autologous uninvolved target cells.  Cytolytic activity was significantly 
greater when IVS effector cells were combined with autologous tumor target cells than with 
autologous benign target cells.  Cytolytic activity was significantly greater when T-reg- 
effector cells were combined with autologous tumor target cells than with autologous 
adjacent uninvolved target cells.  Cytolytic activity was significantly greater when T-reg- 
effector cells were combined with autologous tumor target cells than with autologous benign 
cells.  Finally, T-reg depletion led to higher specific lysis of autologous tumor and benign 
target cells.  Of the 22 OC patients tested, 14 (64%) displayed higher specific lysis of tumor 
target cells after T-reg depletion.   
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Figure 36:  CTL Assay Summary. Target cells pulsed with KSU and an effector to target ratio of 50 
to 1. Human patient autologous cells were used as target cells.  Primary human tissue was 
harvested from OC patients (n=28), uninvolved normal tissue (n=10) and patients with 
benign disease (n=18).  CTL assays were performed using a standard 4-hour 51Cr-release 
assay.  Primary OC tumor and benign cells were pulsed with HERV-K and used as target 
cells.  Cytolytic activity was significantly greater when IVS effector cells were combined 
with autologous tumor target cells than with autologous uninvolved target cells.  Cytolytic 
activity was significantly greater when IVS effector cells were combined with autologous 
tumor target cells than with autologous benign target cells.  Cytolytic activity was 
significantly greater when T-reg effector cells were combined with autologous tumor target 
cells than with autologous adjacent uninvolved target cells.  Cytolytic activity was 
significantly greater when T-reg effector cells were combined with autologous tumor target 
cells than with autologous benign cells. T-reg depletion led to higher specific lysis of 
autologous tumor and benign target cells.  A student’s t-test was used to calculate 
significance between groups. 
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Chapter 4:  Discussion 
Approximately 8.3% of the human genome is derived from HERVs, resulting from 
integration events that took place millions of years ago.  Most HERVs are defective and 
unable to produce infectious particles; however, some of them have retained the capacity to 
encode viral proteins 280.  HERV-K is the only family that has maintained intact ORFs for 
gag, pro, pol, and env.  As discussed previously, HERV genes play important roles in some 
normal physiological events but unfortunately have been associated with several 
autoimmune diseases and cancer.  The expression of HERV-K mRNA and protein and 
production of retroviral particles has been detected in human cancer (Table 1).  The primary 
focus in our laboratory has been on HERV-K expression in BC patients 94-96.  However, in 
2006, our group was the first to report that HERV-K env protein is also expressed on the 
surface and in the cytoplasm of OC cells.  We also determined that expression of HERV-K 
env mRNA was greater in ovarian epithelial tumors than in normal ovarian tissues.   Finally, 
we discovered anti-HERV antibodies in patients with OC, but not in normal female 
controls175.   In this study, we confirm and augment our previous findings by providing 
cogent data on HERV-K expression and the immune responses they trigger in a new cohort 
of patient samples.  
In this study, we amassed blood and tissue samples from patients with OC and patients 
with benign disease.  Within this new patient cohort, several patients provided both OC and 
adjacent uninvolved samples, which were invaluable in determining differences in HERV-K 
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expression within one patient.  Blood samples from normal female donors were also 
collected and compared.   
Our first objective was to determine the expression of HERV-K at the transcriptional 
level in our samples.  Our results show that patients with OC had overall stronger expression 
of HERV-K transcripts compared to patients with benign disease and adjacent uninvolved 
samples.  We had the ability to compare OC and adjacent uninvolved samples, as well as 
OC and benign samples from the same patient.  In every patient pair, HERK-K expression 
was greater in OC than in adjacent uninvolved and benign samples.  Our next objective was 
to determine if HERV-K expression at the translational level showed similar results.   We 
implemented IHC, IFS, FACS and dry cell ELISA to achieve this.   Biopsies from patients 
(n=406) with OC, benign disease and normal epithelium biopsies were assayed.  HERV-K 
expression was detected in endometrioid adenocarcinoma and serous adenocarcinoma 
samples but not in benign cysts or normal epithelium.   IFS data from DOV13, an 
established OC cell line, indicates both surface and cytoplasmic expression of HERV-K 
which substantiates data from our 2006 paper.  IFS analysis shows that human primary cells 
lines, distinctly exhibit greater cell surface expression of HERV-K in OC samples compared 
to benign samples (Figure 8, 10, 11) 
Of great importance was the characterization of our primary human cell lines harvested 
from OC and benign samples.  As mentioned previously, it has been determined that 
epithelial and mesenchymal cells undergo dramatic changes in their cytoskeletal scaffolds 
during tumorigenesis that are sometimes unpredictable.  These observations may be due to 
the fact that tumors have the potential to initiate expression of a novel IF, or alternatively, 
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may cease to express a normally present IF 281.  This infidelity of IF expression has been 
observed in vitro in specific tumor cell lines of human malignancies and includes expression 
of vimentin by epithelial cells, expression of cytokeratin by mesenchymal cells, or 
coexpression of both 251, 262, 263, 281-285.  Indeed Hendrix and his colleagues determined that 
cytokeratin and vimentin positive human BC cells displayed increased invasive potential, 
proliferation rates, clonogenicity, and tumorigenicity compared to cells in which vimentin 
and cytokeratin was transiently down-regulated 263.  In one study, six permanent human 
tumor cell lines established from patients with serous adenocarcinomas of the ovary showed 
co-expression of cytokeratins (7, 8, 17, 18, and 19) and vimentin 286.  In another study, 
Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA, and Hendrix 
MJ determined that tumor cells which expressed both cytokeratin and vimentin in 
approximately equal ratios, translated to poorer survival of these BC patients 254.  To add 
more complexity to this subject, in one study, epithelial cells in most benign breast disease 
samples tested were positive for cytokeratin 8 and 18 287.   Another study showed that co-
expression of cytokeratin and vimentin was found in all benign prostatic epithelium and in 
83% of adenocarcinomas 288.   
In our study, we indeed observed that the majority of OC human primary cells lines 
positively coexpressed vimentin and cytokeratin.   Co-expression was also observed in the 
benign primary cells.  Another group illustrated that loss of cytokeratin 8 and 18 expression 
and concurrent up-regulation of vimentin suggested that disseminated BC tumor cells had 
acquired a mesenchymal-like, aggressive phenotype 247.  Contrary to this, the majority our 
OC and benign primary cells positively expressed cytokeratin 8 and 18.  IFS data displayed 
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the morphological appearance of these vimentin and cytokeratin expressing cells as 
interwoven IF fibers (Table 2 and Figure 8).    
In order to understand this up-regulation of vimentin in our primary patient cells, we 
should observe normal epithelial behavior.  In normal wound healing, epithelial cells 
undergo an epithelial-mesenchymal transition (EMT) whereby their phenotype changes to a 
fibroblastic appearance, enabling them to move into the wound site, after which they 
reconstruct the epithelium by reverting back to an epithelial state via mesenchymal-
epithelial transition (MET).  However, in epithelial carcinomas, cells do not revert back 
from the EMT, and take on an aggressive, invasive role 248.    
Based on their resistance to traditional cancer therapies and presumed ability to 
recapitulate the original tumor, cancer stem cells are believed to be the source of recurrent 
OC 228.  There is growing evidence that tumor initiating cells capable of forming new tumors 
are rare and the majority of cancer cells are nontumorigenic 289.  The notion that cancer is 
driven by tumor initiating cells has obvious therapeutic implications but curative therapy 
should be designed to target these initiating cells instead of the bulk of nontumorigenic cells 
290
.   Therefore, our next objective was to characterize OC stem cell populations in two 
previously described individual patients.  Patient #65 was diagnosed with metastatic 
adenocarcinoma, and the tumor cells from this patient had an epithelial morphology.  Cells 
were harvested on day 1 and then grown in tumorsphere inducing conditions for 6 days.  
RT-PCR confirmed that transcripts for HERV-K Type1 and Type 2, ERV-3, and HERV-
E41 increased upon tumorsphere formation.  QIFIKIT and FACS assay confirmed the 
presence of HERV-K surface expression.  FACS confirmed populations for mesenchyme, 
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epithelial, HERV-K+, and tumor epithelial cells also increased upon tumorsphere formation.  
We also included two antibodies for CD133 and CD44, OC stem cell markers, and 
determined that populations of CD44+ cells increased upon tumorsphere formation. The 
increased expression of HERV-K and CD44 populations indicates that targeting HERV-K in 
OC cells could possibly be beneficial in eradicating stem cell populations (Figure 15).   
The second patient characterized was diagnosed with serous carcinoma which had 
metastasized and formed an ascites.  One day post-harvest, cells took on an epithelial–like 
morphology in culture.  In a recent study, ascites from a patient diagnosed with advanced 
ovarian adenocarcinoma grew in an anchorage-independent manner in vitro as spheroids and 
presented the distinctive phenotype of CD44+cKit+, expressed both epithelial and 
mesenchymal markers and established tumors that were histopathologically similar to those 
in the human disease 291.  Therefore to promote an anchorage-independent, self-renewing 
sphere population, we plated ascites cells in serum-free Epicult media on 0.8% agarose 
coated plates for 7 days 240.  To investigate the phenotypic characteristics of these 
tumorsphere cells, FACS was used to analyze the expression of common OC stem cell 
markers. Indeed, after tumorsphere culture, expression of epithelial, tumor epithelial and 
mesenchymal markers, as well as the cancer stem cell marker CD44 increased, as was also 
observed 291.  CD133 expression decreased slightly Figure 17.  The most valuable 
observation was the concomitant increase HERV-K as the most alluring potential vaccine 
targets are molecules that are associated with cancer stem cells and/or the EMT process 165.  
The similarities between cells undergoing EMT and the acquisition of “stem-like” 
characteristics have been explored by recent studies 292. 
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Moving our focus to immune responses generated by HERV-K, we next compared the 
levels of anti-HERV-K antibodies in serum from OC patients to patients with benign 
disease.  Our results show a positive correlation between anti-HERV-K serum reactivity and 
tumor progression.  In an attempt to discern a pattern in anti-HERV-K antibody levels 
during post-operative spans, the data produced was inconclusive.  Our patient sample cohort 
is limited in terms of samples available during remission, and recurrence and further studies 
will be necessary once additional samples become available (Figure 18-19).   
After identifying a humoral response against HERV-K in OC patients, our next 
objective was to explore HERV-K-specific T-cell responses.  To accomplish this, it was 
very important to first characterize our patient PBMC and IVS populations.  This is critical 
because T cell infiltrates are frequently associated with a favorable prognosis for many 
epithelial cancers 216, 264-272.  However, it is the intricate balance between these effector cells 
and regulatory T cells that determine the critical outcome of the patient. Although changes in 
cell populations were not significant, trends were observed.   In the patient diagnosed with 
benign disease, the positive populations of T helper cells, cytotoxic T cells, activated T and 
B cells, NK cells, and T-regs increased upon conversion from PBMCs to IVS cells. A second 
patient diagnosed with benign disease displayed the same trends except a slight decrease in 
T-regs.   In the patients diagnosed with OC, the positive populations of T helper cells, 
cytotoxic T cells, activated T and B cells increased while positive populations of NK cells 
and T-regs decreased.  These increases in particular effector cell populations are what 
triggered the strong cell-based immune reactions against HERV-K expressing cells in our 
subsequent assays discussed below.  A decrease in T-regs initially appears beneficial but this 
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is hard to discern because the exact balance between effector cells and T-regs is unknown 
(Table 4). 
A profound biological issue in limiting the efficacy of cancer vaccines is the 
limitation on the ability of T cells to expand in number in response to antigenic stimulation.  
Normally, strict biological limits imposed on the immune system to prevent excessive T-cell 
activation and expansion 293.  Therefore, our subsequent goal was to determine if HERV-K 
could induce T cell activation resulting in proliferation of activated T cells.   Our results 
show that T cell proliferation was significantly greater when OC patient IVS cells are 
combined with HERV-K pulsed DC, compared to KLH pulsed DCs.  T cell proliferation is 
also higher when HERV-K pulsed DCs are combined with IVS from OC patients, compared 
to patients with benign disease (Figures20-23).  IFN-γ is secreted by activated CD4+ and 
CD8+ cells, so we next employed an ELISPOT assay, which is a common assay used to 
monitor T cell immune responses. Results show that there are significantly more IFN-γ-
secreting effector cells when IVS cells are combined with HERV-K pulsed DCs, compared 
to IVS cells combined with KLH pulsed IVS cells in OC patients.  Significantly more IFN-
γ-secreting effector cells are seen when IVS cells are combined with HERV-K pulsed DCs in 
OC patients compared to patients with benign disease.  Finally, significantly more IFN-γ-
secreting effector cells are present when IVS cell are combined with HERV-K pulsed DC in 
OC patients compared to PBMCs in OC patients (Figure 23-25).  These results are akin to 
the results seen in our BC patient samples 94.  These results are also parallel to results 
published by Mullins CS and Linnebacher M who discovered that stimulation of T 
peripheral T cells with autologous DCs pulsed with HERV-H retroviral peptides resulted in 
115 
sustained proliferation of predominantly CD8+ T cells and high numbers of IFN-γ secreting 
T cells 294.   
IFN-γ production and proliferation are clear signs of specific activation, however 
they do not prove cytotoxic ability.  CD8+ cytotoxic T lymphocytes are extremely important 
effector cells of the immune system and destroy cells that express foreign antigens on their 
surface.  Thus, our most powerful results are seen in our CTL assays utilizing patient 
lymphocytes and autologous target cells.   Cytolytic activity was significantly greater when 
IVS effector cells were combined with autologous tumor target cells than with autologous 
uninvolved target cells.  Cytolytic activity was also significantly greater when IVS effector 
cells were combined with autologous tumor target cells compared to autologous benign cell 
(Figure 26-27).  Overcoming suppressive mechanisms found within the tumor 
microenvironment in order to enhance efficacy is a major challenge for current approaches 
to cancer vaccination.  Therefore our next goal was to determine the effects of T-reg 
depletion on cytolytic activity.  We discovered that cytolytic activity was significantly 
greater when T-reg effector cells were combined with autologous tumor target cells than 
with autologous adjacent uninvolved target cells.  Also, cytolytic activity was significantly 
greater when T-reg effector cells were combined with autologous tumor target cells than 
with autologous benign cells.  Overall, of all the OC patients tested, 64% displayed higher 
specific lysis of tumor target cells after T-reg depletion (Figure 28-35).  Therefore, future 
vaccine regimens with HERV-K have the potential of an increase in efficacy upon 
combination with T-reg depletion methods.  This is the first report to explore the immune 
responses triggered by HERV-K in OC patients and these results are a beneficial 
contribution supporting optimism for the future of OC immunotherapeutics.  
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Chapter 5:  Conclusion and Future Studies 
5.1  Conclusion 
 The history of cancer immunotherapy began in 1891 when William Coley, a 
surgeon, injected live or inactivated Streptococcus pyogens and Serratia marcescens into the 
tumors of patients in order to reproduce remissions of sarcomas observed in patients with 
erysipelas 295.  The injected toxins were used to stimulate antibacterial phagocytes that might 
kill bystander tumor cells.  However, this approach was never embraced by oncologists 
because of the many risks associated with the administration of infectious agents 215.  
Significant responses in cancer immunology occurred over the following 40 years; however, 
successes were sporadic.  Today, cancer immunotherapy is coming of age with the advent of 
inhibitors that target oncogenic pathways, agents that prime and guide a patient’s immune 
response, and pharmacodynamics biomarkers to identify efficacy of a particular treatment 
215
.  
There are many impediments to success in the cancer vaccine realm.  First, 
expression of the tumor antigen in the target tumor population may be inadequate for 
predicting the ability to generate effective T-cell responses.   In addition, the antigen 
expression within the tumor bed can be heterogeneous and the relative specificity of a 
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tumor-associated antigen may be the same for tumor versus normal adult tissue.  However, 
in our study, we found increased expression of HERV-K in OC samples compared to normal 
control or benign disease samples and evidence that HERV-K indeed generates strong T-cell 
responses.  Secondly, the optimal adjuvant for producing antitumor CD8+ T-cell responses 
that can be used safely and effectively in humans is not yet clear 215.  Finally, the 
effectiveness of a tumor-specific T-cell population may be limited by the multiple 
mechanisms of immunosuppression used by tumors to protect them from T-cells.  However, 
in our study, we found that T-reg depletion resulted in higher specific lysis levels for target 
cells expressing HERV-K.  The development of tumor immunotherapies is an extremely 
active field and characterization of novel tumor-associated antigens is essential because they 
minimize the risk of autoimmunity.  A novel tumor associated antigen has several 
requirements.  First, it is expressed in a significant proportion of patients with a particular 
cancer type.  Secondly, it is not expressed or expressed at low levels in normal tissues.  
Thirdly, it is immunogenic  211.  Our data demonstrates that HERV-K is indeed a novel 
tumor-associated antigen that elicits a strong immune response due to its inherent viral 
quality, making it a strong potential as an OC vaccine.  We have efficaciously asserted that 
impediments to a successful cancer vaccine can be overcome and we look forward with 
unequivocal optimism in this new era of cancer immunotherapy. 
5.2  Future Studies 
The field of therapeutic cancer vaccines has reached several new and significant 
milestones in scientific empiricism.  Great strides have been made in vaccine-delivery 
systems for the induction and enhancement of host antitumor immune responses.  
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Immunostimulants have been shown enhance immunogenic properties of vaccine 
preparations.  Finally, the development and characterization of tumor-associated antigens 
overexpressed only in tumor cells and not normal cells has increased the efficacy and 
decreased the toxicity of vaccines.  There are numerous types of vaccines that have been 
explored in preclinical and clinical trials, and some are currently being evaluated in the 
clinic.  We feel it advantageous to detect successes in these current vaccines and apply or 
combine them with HERV-K in future studies.   
Whole tumor vaccines are advantageous because numerous tumor associated 
antigens and tumor-specific antigens are present.  These tumor cells can either be obtained 
for the same patient or from other patients.    Disadvantages include high costs associated 
with custom vaccine production and considerable variability of tumors among patients 296-
301
.  Additionally, allogenic vaccines produce alloimmunity to nontumor components, 
altering the immune response.  Another vaccine approach involves direct injection of 
cytokine genes or costimulatory molecule genes into the tumor.  B7-1, a T cell costimulatory 
molecule on the surface of antigen-presenting cells, interacts with CD28 for up-regulation of 
T cell function and cytotoxic T lymphocyte-associated antigen (CTLA-4) for down-
regulation of T cell function.  Addition of B7-1 to an immunogenic tumor has been shown to 
make the tumor more immunogenic in preclinical studies 302.  Similar results are seen when 
intercellular adhesion molecule (ICAM)-1 and lymphocyte function-associated antigen 
(LFA)-3 have been added to tumors with marked success. The advantage of this approach is 
that the vaccine contains unique tumor-associated antigens and tumor-specific antigens 
specific to the patient.  Indeed, clinical studies have shown that recombinant vectors 
expressing the B7-1 costimulatory molecule have been directly injected into melanoma and 
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carcinoma lesions 303.  Another clinical study utilizing recombinant vectors containing B7-1, 
ICAM-1 and LFA-3 injected directly into melanoma tumors has exhibited positive results 
304
.  Recombinant vectors containing cytokines can also be used and have been administered 
in preclinical models 305, 306 and in prostate tumors clinically 307.  Vectors expressing GM-
CSF have also been administered in melanoma patients 308.   
Successes have also been shown with administration of peptide-based vaccines 
because peptides do not contain parts of the molecule shared with normal cellular proteins as 
compared to whole proteins.  Peptides are inexpensive, easy to prepare, and minimize the 
potential for autoimmunity.  On the other hand, the inherent specificity of peptides could 
lead to activation of only CD8+ cells inducing a response that is short-lived due to the 
absence of CD4+ cells.  Also, peptides are beneficial only in patients who have a specific 
HLA allele.  Numerous clinical trials are currently testing peptide vaccines including HPV 
309
, ras 310, 311, HER-2/neu 312, MAGE 313, MART-1, tyrosinase 314, gp100 315, 316, CEA 317, 
MUC-1 318, and PSMA 319, 320. 
Vectors as a means of vaccine delivery have also been explored 321-327.  Vector based 
vaccines are advantageous because of the flexibility of inserting the entire tumor antigen, 
just parts of the gene, or multiple genes.  Indeed several clinical trials with recombinant 
vaccinia, a vaccine vector from the poxvirus group, containing tumor-associated antigens 
such as CEA 328, MUC-1, PSA 329, and HPV 315, 330, have been completed and others are 
ongoing 331-333.  Unfortunately, there is the possibility of development of host-induced 
immunity to the vector itself, limiting continued use.   Plasmid DNA vectors are another 
vaccine-delivery system used in studies however, how these vectors induce an immune 
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response is not fully understood 334.  Current clinical trials employing this technique include 
DNA vaccines encoding melanoma antigens such as MART-1 335, gp100 336, and PSA 337.   
DC vaccines have created great excitement in the cancer vaccine field because they 
are the most potent antigen presenting cell 338, 339.  This method involves loading the DC 
with a peptide, protein, anti-idiotype Ab, apoptotic bodies from tumor cells or actually 
fusing it with a tumor cell 340-343.  Unfortunately, DC vaccines are extremely expensive and 
require great effort in isolating and culturing large amounts of PBMCs from each patient.   
In April 2010, the Food and Drug Administration (FDA) approved Provenge 
(sipuleucel-T), the first active immunotherapy approach to cancer treatment.  Provenge is 
comprised of an incompletely characterized, complex mixture of PBMCs supplemented with 
a cytokine and a tumor-derived differentiation antigen, for the treatment of advanced 
prostate cancer.  PBMCs are obtained from the patient via leukapheresis, cultured for several 
days, and then reinfused into the patient.  Even though clinical results showed little evidence 
of tumor shrinkage or delay in disease progression, a 4.1 month improvement in median 
survival was achieved and deemed significant by the FDA.  It is believed that the 
professional antigen-presenting cells activated with the PA2024 fusion protein combined 
with GM-CSF, which produced significant results.   This is a huge accomplishment in the 
field of cancer immunotherapy, and further studies are required to understand the therapeutic 
mechanism of Provenge 344.  Another therapy currently in late-stage phase 3 clinical trials 
involves immunization with autologous DCs loaded ex vivo with a recombinant fusion 
protein consisting of the tumor antigen prostatic acid phosphatase (PAP) linked to GM-CSF 
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345
.  Based on the success of these DC-based vaccines, it might be advantageous to try this 
method with autologous DCs loaded ex vivo with HERV-K in OC patients.   
An imperative issue in the development of cancer vaccines involves the appropriate 
disease stage at which to administer vaccines.  As dictated by medical ethics, all new phase 
1 immunotherapies and many phase 2 trials must be administered to patients with advanced 
disease who have failed conventional therapy.  Therefore, the majority of current vaccines 
focus on late-stage cancer, with little emphasis on preventative or prophylactic vaccines.  
Unfortunately, patients with extensive disease are not ideal candidates in which to determine 
new vaccine efficacy partly because previous therapy could have caused 
immunosuppression.  Therefore, the field of cancer immunotherapy must mature to a point 
where vaccine can be evaluated in patients with early-stage cancers.  This will allow us to 
determine if HERV-K could also be effective in cancers at different stages.  Another 
concern in cancer vaccine development is the possibility of expression of tumor-associated 
antigens in normal cells, leading to undesirable immune reactions.  This deleterious side-
effect was seen experimental and clinical studies when vitiligo was induced in melanoma 
patients 346, 347.  Although HERV-K was not expressed in the normal tissues we studied, 
future HERV-K vaccination clinical studies need to monitor this chance occurrence.   
The data presented here provides the rationale for HERV-K in clinical vaccination 
protocols targeting ovarian tumors expressing HERV-K, however additional assays need to 
be conducted with larger sample sizes in order to ensure that HERV-K is not expressed in 
normal tissues.  If this data reconfirms our data, HERV-K specific vaccination strategies 
have the potential to improve OC patient outcome.  Performance in the clinic is the final 
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arbiter of success in drug development and we believe that HERV-K vaccination should be 
moved into clinical trials without hesitation.  In comparison to other vaccine types we 
believe that the use of a full length HERV-K protein is a superior method because it contains 
a broader profile of epitopes that might be presented by DC.  As innately inquisitive 
scientists, our present study generated other perplexing ideas that we would like to further 
investigate, as discussed below.   
Stromal cells in the tumor environment stimulate epithelial cell proliferation which leads 
to neoplastic transformation.  This dependence of carcinoma cells on stromal support 
explains the difficulty of generating a true microenvironment in vitro.   The interactions 
between these two cell types is extremely complex and involves exchanges of  dozens of 
distinct molecular species that mediate cell-to-cell signaling 243.  Therefore further research 
is necessary in order to correctly assimilate a comparable tumor microenvironment in vitro, 
making it more representative of tumors in patients.  Indeed, instead of focusing on the 
intracellular signaling defects within cancer cells, new cancer therapy is directed toward 
interrupting specific signaling, thereby depriving cancer cells of essential stromal support 
243
.     
As illustrated in Figure 13, after receiving an ascites sample from an OC patient 
diagnosed with serous carcinoma, our goal was to promote stem cell growth with a serum-
free and low adherent environment.  After 7 days in this environment, round spherical 
tumorspheres formed and the population of CD44+ stem cells increased.  Most importantly, 
HERV-K expression increased.   This provides the exciting potential of targeting OC stem 
cells via immunotherapeutic methods by exploiting their increased HERV-K expression.  
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Further studies need to be conducted on the relationship between OC stem cells and HERV-
K expression.    
Numerous studies have indicated that HERVs may be involved in the process of 
tumorigenesis. Therefore, the next step is to determine the causal relationship between 
tumor development and HERV-K expression.  Specifically, the regulation and effector 
pathways of HERV-encoded oncoproteins need to be elucidated.  Currently, a causative role 
of HERVs in human tumors has not been demonstrated and future studies need to clarify this 
issue.  Determining the role of HERVs in the complex multi-step process leading to cancer 
will shed light on the biology of cancer and also the interplay between HERVs and their 
human hosts 33. 
Another thought to contemplate is that the tumor or ascites specimens in our patient 
cohort were obtained at primary surgery.  Therefore, the immunological changes that occur 
during treatment and recurrent disease are unknown and need to be explored.  Also, the 
positive and negative regulatory components in the tumor environment, during these periods 
of treatment and recurrence need to be determined 113.   
As mentioned previously, numerous preclinical studies have presented data on the 
successes of vaccines in combination with other therapeutic modalities; and therefore, future 
studies should determine the effect of combining HERV-K with radiation, chemotherapy, 
hormone therapy, and other immunotherapies.  Recent innovative techniques in 
immunotherapy have been developed in order to overcome the immunogenicity of a weak 
tumor-associated antigen.  These include immunostimulants, adjuvant-like molecules 348, 349, 
microbial products 350, 351, cytokines 352-355, and chemokines.  For example, GM-CSF have 
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been shown to enhance vaccine efficacy in clinical trials 331, 356-359.  Preclinical studies with 
the monoclonal antibody, anti-CTLA-4 combined with vaccines results in higher-avidity 
antigen-specific T cells 360-362.  Preclinical and early clinical studies have shown that vaccine 
in combination with chemotherapeutic agents produces no detrimental effects in the immune 
response 363.  Future studies are needed in order to determine if these elements in 
combination with our vaccine will result in enhancement of T-cell responses and antitumor 
activity.  Hopefully, the use of our vaccine regimen in combination with other therapies 
mentioned above, will present beneficial results. 
MAbs function through several different mechanisms including inhibition of tumor-
related signal transduction, induction of apoptosis, inhibition of angiogenesis, enhancing 
host immune response against cancer and targeted delivery of cytotoxic agents to the tumor 
site.  The most important development for cancer immunotherapy are the results of the 
ipilimumab phase III trials.  The FDA granted broad approval in March 2011 for the use in 
patients with metastatic melanoma, either as an initial therapy or after relapse. Ipilimumab is 
a monoclonal antibody to CTLA4, a negative regulator of T-cell activation, and therefore 
enhances host immune responses against cancer.   Ipilimumab provides clear clinical 
validation for cancer immunotherapy in general 344.  Highlighting a different function of 
mAbs, we previously reported that anti-HERV-K-specific monoclonal antibodies inhibited 
growth and induced apoptosis of breast cancer cells in vitro.  Also, we strengthened these 
results by then showing that mice treated with 6H5 antibody showed statistically reduced 
growth of xenograft tumors compared to mice treated with control mouse IgG, for tumors 
originating from the established BC cells line, MDA-MB-231 96.   Our results also showed 
that binding of the anti-HERV-K antibody to the cell surface env signals through TP53 
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pathway activation.  TP53 is a tumor suppressor gene that plays a key role in apoptosis and 
senescence, activation of DNA repair proteins, and cell cycle arrest at the G1/S regulation 
point during DNA damage recognition.  We believe that either the internalization of the 
complex formed between env and the antibody or signaling through surface env after 
binding of the antibody leads to TP53 pathway activation.  Based on this recent success, we 
would also want to establish whether anti-HERV-K protein antibodies can successfully 
target ovarian tumors with the similar excellence that we accomplished in breast tumors.   In 
Figure 37, the effect of 6H5 on the induction of ovarian cell apoptosis was assessed by annexin 
V flow cytometric assay.  Cells treated with 6H5 mAb induced more early and late apoptosis 
than cells treated with mouse-IgG, thus giving us confidence that anti-HERV-K antibodies could 
show immunotherapeutic potential in targeting ovarian tumors.   We believe that the same 
mechanisms of mAb action are involved as in our BC results however more extensive research 
is needed.   
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Figure 37:  Induction of apoptosis in established OC cells treated with anti-HERV-K 6H5 
antibody.  The induction of ovarian cell apoptosis was assessed by annexin V flow cytometric 
assay. Cells were incubated with either 6H5 mAb (10.0 µg/ml) or mouse-IgG (10.0 µg/ml) for 
16 hours at 37°C. The orange quadrant represents dead cell or cells in late apoptosis, the red 
quadrant represents cells in early apoptosis and the cells in the lower left quadrant represent 
viable cells.  Cells treated with 6H5 mAb induced more early and late apoptosis than cells 
treated with mouse-IgG. 
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Moving forward, knowledge about the immune effects of anticancer mAbs can 
influence our ability to use them therapeutically.  This information can identify biomarkers 
that can enhance our ability to select those patients who are most likely to respond to mAb 
therapy.  Therefore we can use immunoassays in order to personalize medicine for patients.  
We can also modify the mAb structure to modulate effector mechanisms such as the ability 
to bind to FcR or fix complement.  The mechanism of mAb action has not been fully 
elucidated, however there are several potential mechanisms that have been proposed.  
Firstly, the interaction between antibody and tumor antigen may induce apoptosis by 
activating mechanisms of complement-mediated cell death in the tumor cell 364.  Secondly, 
inhibition of ligand-receptor interaction with mAbs can lead to cell death because cells are 
deprived of tumorigenic stimuli such as growth factors for proliferation, differentiation, 
interaction with other cells, growth, and survival 365.  Thirdly, the formation of an entire 
antiidiotype network induces immunological responses against cancer cells and therefore, 
the development of antiidiotype antibodies (Ab2) against Ab1-binding sites is another 
important way of mAb action 366.  The amount of antigen on tumor cells, the subclass of the 
antibody, and the type of effector cell are some additional factors that regulate the ability of 
mAbs to induce ADCC. 
Multimodality approaches, based on synergistic effects observed with the 
combination of antibodies with chemotherapeutic drugs and/or radiotherapy also merit 
further investigation. Immune-mediated effects may be further exploited with the use of 
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bispecific molecules. Stratification of patient sub-populations with tumors overexpressing 
disease-related clinical biomarkers could result in improving both efficacy and specificity of 
antibody-based treatment for solid tumors. 
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